<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Immunoglobulin for multifocal motor neuropathy - Keddie, S - 2022 | Cochrane Library</title> <meta content="Immunoglobulin for multifocal motor neuropathy - Keddie, S - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004429.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Immunoglobulin for multifocal motor neuropathy - Keddie, S - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004429.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004429.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Immunoglobulin for multifocal motor neuropathy" name="citation_title"/> <meta content="Stephen Keddie" name="citation_author"/> <meta content="Institute of Neurology" name="citation_author_institution"/> <meta content="Filip Eftimov" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="f.eftimov@amc.uva.nl" name="citation_author_email"/> <meta content="Leonard H van den Berg" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Ruth Brassington" name="citation_author"/> <meta content="National Hospital for Neurology and Neurosurgery" name="citation_author_institution"/> <meta content="Rob J de Haan" name="citation_author"/> <meta content="Academic Medical Centre, University of Amsterdam" name="citation_author_institution"/> <meta content="Ivo N van Schaik" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD004429.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/01/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004429.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004429.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004429.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Immunoglobulins, Intravenous [therapeutic use]; Plasma Exchange; *Polyneuropathies [drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004429.pub3&amp;doi=10.1002/14651858.CD004429.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004429\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004429\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","th","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004429.pub3",title:"Immunoglobulin for multifocal motor neuropathy",firstPublishedDate:"Jan 11, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004429.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004429.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004429.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004429.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004429.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004429.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004429.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004429.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004429.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004429.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4839 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004429.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/appendices#CD004429-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/table_n/CD004429StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/table_n/CD004429StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Immunoglobulin for multifocal motor neuropathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#CD004429-cr-0004">Stephen Keddie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#CD004429-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Filip Eftimov</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#CD004429-cr-0006">Leonard H van den Berg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#CD004429-cr-0007">Ruth Brassington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#CD004429-cr-0008">Rob J de Haan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information#CD004429-cr-0009">Ivo N van Schaik</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information/en#CD004429-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 January 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004429.pub3">https://doi.org/10.1002/14651858.CD004429.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004429-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004429-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004429-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004429-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004429-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004429-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD004429-abs-0005">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004429-abs-0001" lang="en"> <section id="CD004429-sec-0001"> <h3 class="title" id="CD004429-sec-0001">Background</h3> <p>Multifocal motor neuropathy (MMN) is a rare, probably immune‐mediated disorder characterised by slowly progressive, asymmetric, distal weakness of one or more limbs with no objective loss of sensation. It may cause prolonged periods of disability. Treatment options for MMN are few. People with MMN do not usually respond to steroids or plasma exchange. Uncontrolled studies have suggested a beneficial effect of intravenous immunoglobulin (IVIg). This is an update of a Cochrane Review first published in 2005, with an amendment in 2007. We updated the review to incorporate new evidence. </p> </section> <section id="CD004429-sec-0002"> <h3 class="title" id="CD004429-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of intravenous and subcutaneous immunoglobulin in people with MMN. </p> </section> <section id="CD004429-sec-0003"> <h3 class="title" id="CD004429-sec-0003">Search methods</h3> <p>We searched the following databases on 20 April 2021: the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and WHO ICTRP for randomised controlled trials (RCTs) and quasi‐RCTs, and checked the reference lists of included studies. </p> </section> <section id="CD004429-sec-0004"> <h3 class="title" id="CD004429-sec-0004">Selection criteria</h3> <p>We considered RCTs and quasi‐RCTs examining the effects of any dose of IVIg and subcutaneous immunoglobulin (SCIg) in people with definite or probable MMN for inclusion in the review. Eligible studies had to have measured at least one of the following outcomes: disability, muscle strength, or electrophysiological conduction block. We used studies that reported the frequency of adverse effects to assess safety. </p> </section> <section id="CD004429-sec-0005"> <h3 class="title" id="CD004429-sec-0005">Data collection and analysis</h3> <p>Two review authors independently reviewed the literature searches to identify potentially relevant trials, assessed risk of bias of included studies, and extracted data. We followed standard Cochrane methodology. </p> </section> <section id="CD004429-sec-0006"> <h3 class="title" id="CD004429-sec-0006">Main results</h3> <p>Six cross‐over RCTs including a total of 90 participants were suitable for inclusion in the review. Five RCTs compared IVIg to placebo, and one compared IVIg to SCIg. Four of the trials comparing IVIg versus placebo involved IVIg‐naive participants (induction treatment). In the other two trials, participants were known IVIg responders receiving maintencance IVIg at baseline and were then randomised to maintenance treatment with IVIg or placebo in one trial, and IVIg or SCIg in the other. Risk of bias was variable in the included studies, with three studies at high risk of bias in at least one risk of bias domain. </p> <p>IVIg versus placebo (induction treatment): three RCTs including IVIg‐naive participants reported a disability measure. Disability improved in seven out of 18 (39%) participants after IVIg treatment and in two out of 18 (11%) participants after placebo (risk ratio (RR) 3.00, 95% confidence interval (CI) 0.89 to 10.12; 3 RCTs, 18 participants; low‐certainty evidence). The proportion of participants with an improvement in disability at 12 months was not reported. Strength improved in 21 out of 27 (78%) IVIg‐naive participants treated with IVIg and one out of 27 (4%) participants who received placebo (RR 11.00, 95% CI 2.86 to 42.25; 3 RCTs, 27 participants; low‐certainty evidence). IVIg treatment may increase the proportion of people with resolution of at least one conduction block; however, the results were also consistent with no effect (RR 7.00, 95% CI 0.95 to 51.70; 4 RCTs, 28 participants; low‐certainty evidence). </p> <p>IVIg versus placebo (maintenance treatment): a trial that included participants on maintenance IVIg treatment reported an increase in disability in 17 out of 42 (40%) people switching to placebo and seven out of 42 (17%) remaining on IVIg (RR 2.43, 95% CI 1.13 to 5.24; 1 RCT, 42 participants; moderate‐certainty evidence) and a decrease in grip strength in 20 out of 42 (48%) participants after a switch to placebo treatment compared to four out of 42 (10%) remaining on IVIg (RR 0.20, 95% CI 0.07 to 0.54; 1 RCT, 42 participants; moderate‐certainty evidence). </p> <p>Adverse events, IVIg versus placebo (induction or maintenance): four trials comparing IVIg and placebo reported adverse events, of which data from two studies could be meta‐analysed. Transient side effects were reported in 71% of IVIg‐treated participants versus 4.8% of placebo‐treated participants in these studies. The pooled RR for the development of side effects was 10.33 (95% CI 2.15 to 49.77; 2 RCTs, 21 participants; very low‐certainty evidence). There was only one serious side effect (pulmonary embolism) during IVIg treatment. </p> <p>IVIg versus SCIg (maintenance treatment): the trial that compared continuation of IVIg maintenance versus SCIg maintenance did not measure disability. The evidence was very uncertain for muscle strength (standardised mean difference 0.08, 95% CI −0.84 to 1.00; 1 RCT, 9 participants; very low‐certainty evidence). The evidence was very uncertain for the number of people with side effects attributable to treatment (RR 0.50, 95% CI 0.18 to 1.40; 1 RCT, 9 participants; very low‐certainty evidence). </p> </section> <section id="CD004429-sec-0007"> <h3 class="title" id="CD004429-sec-0007">Authors' conclusions</h3> <p>Low‐certainty evidence from three small RCTs shows that IVIg may improve muscle strength in people with MMN, and low‐certainty evidence indicates that it may improve disability; the estimate of the magnitude of improvement of disability has wide CIs and needs further studies to secure its significance. Based on moderate‐certainty evidence, it is probable that most IVIg responders deteriorate in disability and muscle strength after IVIg withdrawal. SCIg might be an alternative treatment to IVIg, but the evidence is very uncertain. More research is needed to identify people in whom IVIg withdrawal is possible and to confirm efficacy of SCIg as an alternative maintenance treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004429-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004429-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004429-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004429-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004429-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD004429-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD004429-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004429-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004429-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD004429-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD004429-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004429-abs-0002" lang="en"> <h3>Intravenous immunoglobulin for multifocal motor neuropathy</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) in people with multifocal motor neuropathy (MMN). Immunoglobulin is a preparation of antibodies with no specific target purified from the blood and is usually given into a vein (intravenous immunoglobulin; IVIg); however, infusions under the skin (SCIg) might be an alternative. </p> <p><b>Background</b> </p> <p>MMN is a rare condition that causes weakness of the limbs, which tends to worsen over time. The arms, especially the hands, are more often involved than the legs. The usual treatment for MMN is IVIg. </p> <p><b>Study characteristics</b> </p> <p>We searched widely for studies on this topic and found six small trials involving a total of 90 people with MMN who received IVIg treatment. Three studies had limitations, and there was not enough information about the remaining studies to permit a full assessment. Five trials compared an infusion (slow injection) of IVIg with a dummy infusion. The remaining trial compared two different administration routes: IVIg infusion versus SCIg infusion. The effects were measured between 4 and 12 weeks after treatment. Two trials involved employees of an immunoglobulin manufacturer as authors. One of these studies, which was also sponsored by the manufacturer, underwent independent manuscript review by experts with full data access. </p> <p><b>Key results and certainty of the evidence</b> </p> <p>IVIg may improve strength in people with MMN. IVIg may also improve disability, but we need further research to confirm or rule out an effect, as this evidence is less certain. The evidence for whether more people experience side effects on IVIg than with a dummy infusion is uncertain. There was only one serious side effect (pulmonary embolism) during IVIg treatment. Most people with MMN need ongoing immunoglobulin treatment, as disability and muscle strength probably deteriorate with immunoglobulin withdrawal. We need more evidence on whether SCIg might be an alternative to IVIg. </p> <p>The evidence is current to April 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004429-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004429-sec-0107"></div> <h3 class="title" id="CD004429-sec-0108">Implications for practice</h3> <section id="CD004429-sec-0108"> <p>Evidence from small randomised controlled trials (RCTs) shows that there may be an improvement in disability in people with multifocal motor neuropathy (MMN) after intravenous immunoglobulin (IVIg) compared with placebo; however, our confidence in the estimate will be increased with further studies. There may be an improvement in muscle strength. As weakness is the only determinant of disability in people with MMN, increase in muscle strength, and especially grip strength, can be used to assess individual response to IVIg. However, improvement in disability is the primary goal of treatment and the main parameter on which to decide whether to continue treatment. People whose complaints do not interfere with daily life are often closely followed without treatment, given the minimal expected benefit of treatment, the burden of regular infusions, and high treatment costs. </p> <p>In most, but not all, people with MMN receiving maintenance IVIg treatment, IVIg withdrawal leads to deterioration in disability and muscle strength. There is very limited evidence from a single, small RCT on the use of subcutaneous immunoglobulin (SCIg) as an alternative to IVIg maintenance treatment. The evidence on adverse effects with IVIg compared to placebo or SCIg is very limited. </p> </section> <h3 class="title" id="CD004429-sec-0109">Implications for research</h3> <section id="CD004429-sec-0109"> <p>In addition to the limited evidence of IVIg efficacy in MMN from RCTs, increase of muscle strength has been confirmed by larger retrospective cohort studies. RCTs with large numbers of newly diagnosed patients to confirm improvement in disability are unlikely given the rarity of disease and the current evidence of IVIg efficacy in increasing muscle strength. In general, for cross‐over trials in rare diseases such as MMN, it is recommended that sufficient data be provided and that analysis be performed in such a way that allows future pooling of paired data, which was not possible in this meta‐analysis. Prospective international registries could be useful in providing evidence based on larger numbers of people, focusing on improvement in disability. Newer and more responsive disability scales such as the Rasch Overall Disability Scale (RODS) might be better than the disability scales used in previous RCTs. More importantly, a prospective registry should identify predictors of ongoing disease activity and provide guidance on how to individualise maintenance treatment. </p> <p>SCIg might be an alternative to IVIg maintenance treatment, but confirmation from RCTs with larger numbers is needed. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004429-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004429-sec-0008"></div> <div class="table" id="CD004429-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">IVIg compared to placebo for multifocal motor neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IVIg compared to placebo for multifocal motor neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with multifocal motor neuropathy<br/><b>Settings:</b> variable: home, centre, or study site<br/><b>Intervention:</b> intravenous immunoglobulin (IVIg)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVIg</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Induction</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with an improvement in disability scale used in the original study </p> <p>Follow‐up: 2 to 6 weeks after the last IVIg treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 100<br/>(10 to 112) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b><br/>(0.89 to 10.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (36 observations)<br/>(3 cross‐over RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg treatment may improve disability, although the result is also consistent with no effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with an improvement of muscle strength</p> <p>Follow‐up: 2 to 6 weeks after the last IVIg treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 100<br/>(11 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11.00</b><br/>(2.86 to 42.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (54 observations)<br/>(3 cross‐over RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg treatment may improve muscle strength.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with an improvement in disability at 12 months or later</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants in which at least 1 conduction block resolved after therapy</p> <p>Follow‐up: 2 to 6 weeks after the last IVIg treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 100</p> <p>(event rate 0 in 28)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> <p>(event rate 6 in 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.00</b> </p> <p>(0.95 to 51.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (56 observations)</p> <p>(4 cross‐over RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg treatment may increase the proportion of people with resolution of at least 1 conduction block; however, the data are also consistent with no effect. </p> <p>In general, spontaneous resolution of conduction block is considered rare, although axonal damage can lead to too low amplitudes to assess the presence of a conduction block. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Maintenance</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as determined and defined by study authors </p> <p>Follow‐up: day 8 of 2‐week treatment cycle, day 15 of those treated every 3 or 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 100<br/>(19 to 87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b><br/>(1.13 to 5.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (84 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg withdrawal probably leads to deterioration in disability.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal </p> <p>Follow‐up: day 8 of 2‐week treatment cycle, day 15 of those treated every 3 or 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100 (3 to 26)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.2</b> (0.07 to 0.54)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (84 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg withdrawal probably leads to deterioration in muscle strength.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Adverse effects (induction or maintenance)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with side effects attributable to treatment</p> <p>Follow‐up: day 8 of 2‐week treatment cycle, day 15 of those treated every 3 or 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 100 (10 to 100)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 10.33</b><br/>(2.15 to 49.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (42 observations)<br/>(2 cross‐over RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is too uncertain to determine whether adverse effects attributable to treatment are more or less common with IVIg than with placebo. </p> <p>1 trial report did not mention adverse effects. In 1 trial, minor adverse effects occurred but were not attributed to individual participants and therefore could not be included in the meta‐analysis. A third trial reported the number of infusions in which adverse events occurred and not the number of participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IVIg:</b> intravenous immunoglobulin; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b><br/>  </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision: small sample size.<br/><sup>b</sup>Downgraded once for study limitations: the studies provided insufficient detail for some risk of bias assessments, and two studies were at high risk of bias for blinding. Although the scales used to measure disability in the included studies were not tailored to multifocal motor neuropathy, this did not warrant further downgrading for indirectness.<br/><sup>c</sup>We downgraded a second time for imprecision, as only six events occurred. We did not further downgrade the evidence for study limitations, as diagnosis of a conduction block is unlikely to be affected by lack of blinding.<br/><sup>d</sup>We did not downgrade for study limitations. Although the trial was at unclear risk of other bias due to a short placebo period with possible incomplete IVIg wash‐out, this would tend to lead to an underestimation of withdrawal effects rather than an exaggeration.<br/><sup>e</sup>We downgraded the evidence a second time for imprecision, as the evidence involved two small trials and few events. We also downgraded the evidence because the studies provided insufficient detail for some risk of bias assessments, and one of the two trials was at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004429-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">IVIg compared to SCIg for multifocal motor neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IVIg compared to SCIg for multifocal motor neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with multifocal motor neuropathy<br/><b>Settings:</b> initial short hospital stay of 1 to 3 days, followed by self‐administration at home supervised by telephone calls from the study nurse<br/><b>Intervention:</b> intravenous immunoglobulin (IVIg)<br/><b>Comparison:</b> subcutaneous immunoglobulin (SCIg) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SCIg</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVIg</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Induction</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No trial studied the use of SCIg for induction. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Maintenance</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in mean muscle strength in participants on IVIg treatment at study entry</p> <p>Follow‐up: 10 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in mean muscle strength in participants on IVIg treatment at study entry in the intervention group was <b>0.08 SD higher</b> (−0.84 lower to 1.00 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (18 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain for the effects on muscle strength of maintenance treatment with SCIg vs IVIg. </p> <p> </p> <p>As a rule of thumb, an effect size of 0.2 would be a small effect; 0.08 is unlikely to be important (<a href="./references#CD004429-bbs2-0039" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates Inc, 1988.">Cohen 1988</a>). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with side effects attributable to treatment</p> <p>Follow‐up: baseline to final evaluation 105 days (45 to 140)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> (12 to 93)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.50 (0.18 to 1.40)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (18 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain for adverse effects attributable to maintenance treatment with SCIg vs IVIg. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IVIg</b> : intravenous immunoglobulin; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>SCIg:</b> subcutaneous immunoglobulin; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations: a single‐blinded RCT in which participants were not blinded for outcome. The study period per treatment arm varied between 54 and 168 days, which may have led to a considerable carry‐over effect in receiving SCIg, especially in participants with a shorter treatment period.<br/><sup>b</sup>Downgraded twice for imprecision: a single trial with a small sample size (9 people, 18 observations). The event rate for adverse events was very low (3 of 9 participants on IVIg versus 6 of 9 participants on placebo). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004429-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004429-sec-0009"></div> <section id="CD004429-sec-0010"> <h3 class="title" id="CD004429-sec-0010">Description of the condition</h3> <p>Multifocal motor neuropathy (MMN) is characterised by slowly progressive, asymmetric, predominantly distal weakness of one or more limbs with no objective loss of sensation (<a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>; <a href="./references#CD004429-bbs2-0070" title="LewisRA , SumnerAJ , BrownMJ , AsburyAK . Multifocal demyelinating neuropathy with persistent conduction block. Neurology1982;32(9):958-64.">Lewis 1982</a>; <a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>; <a href="./references#CD004429-bbs2-0083" title="Nobile-OrazioE , CappellariA , MeucciN , CarpoM , TerenghiF , BersanoA , et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. Journal of Neurology, Neurosurgery and Psychiatry2002;72(6):761-6.">Nobile‐Orazio 2002</a>). This weakness may be accompanied by muscular atrophy in later stages of the disease, and cramps and fasciculations are reported to occur in approximately 50% of people with MMN (<a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>). The arms are usually more affected than the legs (<a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>; <a href="./references#CD004429-bbs2-0083" title="Nobile-OrazioE , CappellariA , MeucciN , CarpoM , TerenghiF , BersanoA , et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. Journal of Neurology, Neurosurgery and Psychiatry2002;72(6):761-6.">Nobile‐Orazio 2002</a>; <a href="./references#CD004429-bbs2-0109" title="Van den Berg-VosRM , FranssenH , WokkeJHJ , Van EsHW , Van den BergLH . Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology2000;48(6):919-26.">Van den Berg‐Vos 2000a</a>). Tendon reflexes are often decreased or absent in the affected limb, but can also be brisk in a minority of people with MMN (<a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>). Cranial nerve involvement and respiratory failure due to phrenic nerve palsy have occasionally been reported (<a href="./references#CD004429-bbs2-0033" title="BeydounSR , CopelandD . Bilateral phrenic neuropathy as a presenting feature of multifocal motor neuropathy with conduction block. Muscle &amp; Nerve2000;23(4):556-9.">Beydoun 2000</a>; <a href="./references#CD004429-bbs2-0035" title="CavalettiG , ZinconeA , MarzoratiL , FrattolaL , MolteniF , NavalesiP . Rapidly progressive multifocal motor neuropathy with phrenic nerve paralysis: effect of nocturnal assisted ventilation. Journal of Neurology1998;245(9):613-6.">Cavaletti 1998</a>; <a href="./references#CD004429-bbs2-0061" title="KajiR , ShibasakiH , KimuraJ . Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology1992;42(3):506-9.">Kaji 1992</a>; <a href="./references#CD004429-bbs2-0096" title="PringleCE , BeldenJ , VeitchJE , BrownWF . Multifocal motor neuropathy presenting as ophthalmoplegia. Muscle &amp; Nerve1997;20(3):347-51.">Pringle 1997</a>). Recently, the extent of sensory signs and symptoms in MMN has been reconsidered, and the development of electrophysiological sensory changes with or without sensory signs and symptoms over the course of MMN have been described (<a href="./references#CD004429-bbs2-0067" title="LambrecqV , KrimE , Rouanet-LarrivièreM , LaguenyA . Sensory loss in multifocal motor neuropathy: a clinical and electrophysiological study. Muscle &amp; Nerve2009;39(2):131-6.">Lambrecq 2009</a>; <a href="./references#CD004429-bbs2-0071" title="LievensI , FournierE , VialaK , MaisonobeT , BoucheP , LégerJM . Multifocal motor neuropathy: a retrospective study of sensory nerve conduction velocities in long-term follow-up of 21 patients. Revue Neurologique2009;165(3):243-8.">Lievens 2009</a>). </p> <p>The hallmark of the disease is the presence of multifocal conduction block on electrophysiological testing outside the usual sites of nerve compression (<a href="./references#CD004429-bbs2-0040" title="CornblathDR , SumnerAJ , DaubeJ , GilliatRW , BrownWF , ParryGJ , et al. Conduction block in clinical practice. Muscle &amp; Nerve1991;14(9):869-71.">Cornblath 1991</a>; <a href="./references#CD004429-bbs2-0060" title="KajiR , KimuraJ . Nerve conduction block. Current Opinion in Neurology and Neurosurgery1991;4(5):744-8.">Kaji 1991</a>; <a href="./references#CD004429-bbs2-0091" title="ParryGJ , SumnerAJ . Multifocal motor neuropathy. In: DyckPJ , ThomasPK , GriffinJW , editors(s). Neurologic Clinics. Peripheral Neuropathy: New Concepts and Treatments. 1st edition. Philadelphia: WB Saunders Company, 1992:671-84.">Parry 1992</a>; <a href="./references#CD004429-bbs2-0092" title="ParryGJ . Motor neuropathy with multifocal conduction block. Seminars in Neurology1993;13(3):269-75.">Parry 1993</a>; <a href="./references#CD004429-bbs2-0106" title="Van AsseldonkJTH , Van den BergLH , Van den Berg-VosRM , WienekeGH , WokkeJHJ , FranssenH . Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain2003;126(1):186-98.">Van Asseldonk 2003</a>). However, some people with otherwise typical MMN have no detectable conduction block, probably because these blocks are activity‐dependent (<a href="./references#CD004429-bbs2-0085" title="NoderaH , BostockH , IzumiY , NakamuraK , UrushiharaR , SakamotoT , et al. Activity-dependent conduction block in multifocal motor neuropathy: magnetic fatigue test. Neurology2006;67(2):280-7.">Nodera 2006</a>), or are located in nerve segments which cannot be assessed by routine electrophysiological examination (<a href="./references#CD004429-bbs2-0045" title="DelmontE , AzulayJP , GiorgiR , AttarianS , VerschuerenA , UzenotD , et al. Multifocal motor neuropathy with and without conduction block: a single entity?Neurology2006;67(4):592-6.">Delmont 2006</a>; <a href="./references#CD004429-bbs2-0090" title="PakiamAS , ParryGJ . Multifocal motor neuropathy without overt conduction block. Muscle &amp; Nerve1998;21(2):243-5.">Pakiam 1998</a>). Conduction block is a reduction in the amplitude or area (or both) of the compound muscle action potential (CMAP) obtained by proximal versus distal stimulation of motor nerves in the absence of or with only focal abnormal temporal dispersion (<a href="./references#CD004429-bbs2-0040" title="CornblathDR , SumnerAJ , DaubeJ , GilliatRW , BrownWF , ParryGJ , et al. Conduction block in clinical practice. Muscle &amp; Nerve1991;14(9):869-71.">Cornblath 1991</a>; <a href="./references#CD004429-bbs2-0062" title="KajiR . Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle &amp; Nerve2003;27(3):285-96.">Kaji 2003</a>; <a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>). The extent of reduction of the CMAP amplitude or area necessary for conduction block, or both, is still a matter of debate. Definite conduction block is usually defined as an area reduction of 50% or more between proximal versus distal stimulation in a long nerve segment or an amplitude reduction of 30% or more over 2.5 cm (<a href="./references#CD004429-bbs2-0050" title="FranssenH , VermeulenM , JennekensFG . Chronic inflammatory neuropathies. In: EmeryAEH , editors(s). Diagnostic Criteria for Neuromuscular Disorders. 2nd edition. London: Royal Society of Medicine Press, 1997:53-9.">Franssen 1997</a>; <a href="./references#CD004429-bbs2-0099" title="RheeEK , EnglandJD , SumnerAJ . A computer simulation of conduction block: effects produced by actual conduction block versus interphase cancellation. Annals of Neurology1990;28(2):146-56.">Rhee 1990</a>; <a href="./references#CD004429-bbs2-0107" title="Van AsseldonkJTH , Van den BergLH , WienekeGH , WokkeJH , FranssenH . Criteria for conduction block based on computer simulation studies of nerve conduction with human data obtained in the forearm segment of the median nerve. Brain2006;129(Pt 9):2447-60.">Van Asseldonk 2006</a>). Probable conduction block is usually defined as an amplitude reduction of 30% or more between proximal versus distal stimulation in an arm nerve (<a href="./references#CD004429-bbs2-0030" title="AlbersJW , DonofrioPD , McGonagleTK . Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle &amp; Nerve1985;8(6):528-39.">Albers 1985</a>; <a href="./references#CD004429-bbs2-0087" title="OhSJ , KimDE , KuruogluHR . What is the best diagnostic index of conduction block and temporal dispersion?Muscle &amp; Nerve1994;17(5):489-93.">Oh 1994</a>). </p> <p>Three main lines of evidence suggest that MMN is an immune‐mediated disorder.</p> <p> <ul id="CD004429-list-0001"> <li> <p>Thirty per cent to 80% of people with MMN have serum immunoglobulin M (IgM) ganglioside‐monosialic acid (GM1) antibodies (<a href="./references#CD004429-bbs2-0113" title="Van SchaikIN , BossuytPMM , BrandA , VermeulenM . The diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology1995;45(8):1570-7.">Van Schaik 1995</a>; <a href="./references#CD004429-bbs2-0117" title="WillisonHJ , YukiN . Peripheral neuropathies and anti-glycolipid antibodies. Brain2002;125(12):2591-625.">Willison 2002</a>). These antibodies are not specific to MMN and can be found in various other immune‐mediated neuropathies such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillain‐Barré syndrome (GBS). Furthermore, it has been shown that antibody titres do not correlate with clinical severity over time (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0108" title="Van den BergLH , FranssenH , WokkeJH . The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain1998;121(Pt 3):421-8.">Van den Berg 1998</a>). </p> </li> <li> <p>Increased signal intensities on T2‐weighted magnetic resonance images of the brachial plexus have been observed in people with MMN, suggesting an inflammatory process (<a href="./references#CD004429-bbs2-0111" title="Van EsHW , Van den BergLH , FranssenH , WitkampTD , RamosLM , NotermansNC , et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology1997;48(5):1218-24.">Van Es 1997</a>). </p> </li> <li> <p>Response to immune‐modulating treatment. The efficacy of human polyclonal immunoglobulin administered intravenously (IVIg) has been suggested in many open and uncontrolled studies. Elevated anti‐GM1 antibodies have been suggested to be a reliable predictor of a favourable response after IVIg treatment (<a href="./references#CD004429-bbs2-0109" title="Van den Berg-VosRM , FranssenH , WokkeJHJ , Van EsHW , Van den BergLH . Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology2000;48(6):919-26.">Van den Berg‐Vos 2000a</a>). However, a considerable number of participants lack these antibodies but do respond favourably to IVIg treatment (<a href="./references#CD004429-bbs2-0032" title="AzulayJP , RihetP , PougetJ , CadorF , BlinO , BoucrautJ , et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. Journal of Neurology, Neurosurgery and Psychiatry1997;62(4):391-4.">Azulay 1997</a>; <a href="./references#CD004429-bbs2-0034" title="BoucheP , MoulonguetA , Younes-ChennoufiAB , AdamsD , BaumannN , MeiningerV , et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. Journal of Neurology, Neurosurgery and Psychiatry1995;59(1):38-44.">Bouche 1995</a>; <a href="./references#CD004429-bbs2-0036" title="ChaudhryV , CorseAM , CornblathDR , KunclRW , DrachmanDB , FreimerML , et al. Multifocal motor neuropathy: response to human immune globulin. Annals of Neurology1993;33(3):237-42.">Chaudhry 1993</a>; <a href="./references#CD004429-bbs2-0064" title="KatzJS , WolfeGI , BryanWW , JacksonCE , AmatoAA , BarohnRJ . Electrophysiologic findings in multifocal motor neuropathy. Neurology1997;48(3):700-7.">Katz 1997</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). A beneficial effect of cyclophosphamide (<a href="./references#CD004429-bbs2-0036" title="ChaudhryV , CorseAM , CornblathDR , KunclRW , DrachmanDB , FreimerML , et al. Multifocal motor neuropathy: response to human immune globulin. Annals of Neurology1993;33(3):237-42.">Chaudhry 1993</a>; <a href="./references#CD004429-bbs2-0048" title="FeldmanEL , BrombergMB , AlbersJW , PestronkA . Immunosuppressive treatment in multifocal motor neuropathy. Annals of Neurology1991;30(3):397-401.">Feldman 1991</a>; <a href="./references#CD004429-bbs2-0066" title="KrarupC , StewartJD , SumnerAJ , PestronkA , LiptonSA . A syndrome of asymmetric limb weakness with motor conduction block. Neurology1990;40(1):118-27.">Krarup 1990</a>; <a href="./references#CD004429-bbs2-0076" title="MeucciN , CappellariA , BarbieriS , ScarlatoG , Nobile-OrazioE . Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1997;63(6):765-9.">Meucci 1997</a>; <a href="./references#CD004429-bbs2-0093" title="PestronkA , CornblathDR , IlyasAA , BabaH , QuarlesRH , GriffinJW , et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Annals of Neurology1988;24(1):73-8.">Pestronk 1988</a>; <a href="./references#CD004429-bbs2-0111" title="Van EsHW , Van den BergLH , FranssenH , WitkampTD , RamosLM , NotermansNC , et al. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology1997;48(5):1218-24.">Van Es 1997</a>), interferon‐beta 1a (<a href="./references#CD004429-bbs2-0074" title="MartinaIS , vanDoornPA , SchmitzPI , MeulsteeJ , van derMechéFG . Chronic motor neuropathies: response to interferon-beta 1a after failure of conventional therapies. Journal of Neurology, Neurosurgery and Psychiatry1999;66(2):197-201.">Martina 1999</a>; <a href="./references#CD004429-bbs2-0110" title="Van den Berg-VosRM , Van den BergLH , FranssenH , Van DoornPA , MerkiesISJ , WokkeJHJ . Treatment of multifocal motor neuropathy with interferon beta 1a. Neurology2000;54(7):1518-21.">Van den Berg‐Vos 2000b</a>), ciclosporin (<a href="./references#CD004429-bbs2-0080" title="NemniR , SantuccioG , CalabreseE , GalardiG , CanalN . Efficacy of cyclosporine treatment in multifocal motor neuropathy. Journal of Neurology2003;250(9):1118-20.">Nemni 2003</a>), methotrexate (<a href="./references#CD004429-bbs2-0084" title="Nobile-OrazioE , TerenghiF , CocitoD , GalliaF , CasellatoC . Oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy on chronic IVIg therapy. Journal of the Peripheral Nervous System2009;14(3):203-5.">Nobile‐Orazio 2009</a>), and azathioprine (<a href="./references#CD004429-bbs2-0053" title="Hausmanowa-PetrusewiczI , Rowińska-MarcińskaK , KopećA . Chronic acquired demyelinating motor neuropathy. Acta Neurologica Scandinavica1991;84(1):40-5.">Hausmanowa‐Petrusewicz 1991</a>) in MMN has been suggested in several uncontrolled studies and reviewed in another Cochrane Review (<a href="./references#CD004429-bbs2-0105" title="UmapathiT , HughesRAC , Nobile-OrazioE , Léger J-M. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD003217. [DOI: 10.1002/14651858.CD003217.pub5]">Umapathi 2015</a>). </p> </li> </ul> </p> <p>Almost 80% of people with MMN are between 20 and 50 years of age at onset of the disease (<a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>). Men are more frequently affected than women, with a ratio of 2.6:1 (<a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>). The prevalence is estimated to be 1 to 2 per 100,000 (<a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>). The diagnosis of MMN is based on clinical, laboratory, and electrophysiological characteristics (<a href="./references#CD004429-bbs2-0058" title="HughesRAC . 79th ENMC International Workshop: Multifocal motor neuropathy: 14-15 April 2000, Hilversum, The Netherlands. Neuromuscular Disorders2001;11(3):309-14.">Hughes 2001</a>; <a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>; <a href="./references#CD004429-bbs2-0091" title="ParryGJ , SumnerAJ . Multifocal motor neuropathy. In: DyckPJ , ThomasPK , GriffinJW , editors(s). Neurologic Clinics. Peripheral Neuropathy: New Concepts and Treatments. 1st edition. Philadelphia: WB Saunders Company, 1992:671-84.">Parry 1992</a>; <a href="./references#CD004429-bbs2-0109" title="Van den Berg-VosRM , FranssenH , WokkeJHJ , Van EsHW , Van den BergLH . Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology2000;48(6):919-26.">Van den Berg‐Vos 2000a</a>; <a href="./references#CD004429-bbs2-0114" title="Van SchaikIN , BoucheP , IllaI , LégerJM , Van den BerghP , CornblathDR , et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Journal of the Peripheral Nervous System2010;15(4):295-301. [DOI: 10.1111/j.1529-8027.2010.00290.x.] [PMID: PMID: 21199100]">Van Schaik 2010</a>). A set of diagnostic criteria has been proposed that combines clinical, laboratory, and electrophysiological features of people with MMN, which may help to predict whether individuals will respond to treatment (<a href="./references#CD004429-bbs2-0109" title="Van den Berg-VosRM , FranssenH , WokkeJHJ , Van EsHW , Van den BergLH . Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology2000;48(6):919-26.">Van den Berg‐Vos 2000a</a>). The American Association of Electrodiagnostic Medicine has developed five criteria through a formal consensus process for diagnosing MMN with a high level of confidence (<a href="./references#CD004429-bbs2-0088" title="OlneyRK , LewisRA , PutnamTD , CampelloneJVJ . Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle &amp; Nerve2003;27(1):117-21.">Olney 2003</a>). These criteria for definite MMN are: weakness without objective sensory loss in the distribution of two or more nerves; definite conduction block in two or more nerves outside of common entrapment sites; normal sensory nerve conduction velocity across the same segments with demonstrated motor conduction block; normal results for sensory nerve conduction studies on all tested nerves, with a minimum of three nerves tested; and absence of upper motor neuron signs. The criteria for probable MMN are somewhat less strict for conduction block. </p> </section> <section id="CD004429-sec-0011"> <h3 class="title" id="CD004429-sec-0011">Description of the intervention</h3> <p>Immunoglobulins (Igs) are proteins produced by the immune system to neutralise pathogens. Ig is harvested from pooled blood (plasma) from healthy donors and used therapeutically after purification. Normal human Ig preparations consist of IgG (90% to 98%) and varying small amounts of IgM and IgA isotypes (<a href="./references#CD004429-bbs2-0031" title="9 human immunoglobulins. Transfusion Medicine and Hemotherapy2009;36(6):449-59.">Anonymous 2009</a>).  </p> <p>Ig can be administered through intramuscular injection, intravenously (IVIg), or subcutaneously (SCIg). The first IVIg treatment is administered at a dose of 2 g/kg body weight over two to five days. After this so‐called loading dose, most people require maintenance treatment at a lower dose and at varying intervals, usually every two to four weeks. When SCIg is chosen for maintenance treatment, patients are first treated with a loading dose of IVIg (<a href="./references#CD004429-bbs2-0081" title="NHS England. Updated Commissioning Guidance for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England December 2018. Available at www.england.nhs.uk/wp-content/uploads/2019/03/PSS9-Immunoglobulin-Commissioning-Guidance-CQUIN-1920.pdf.">NHS England 2018</a>). </p> <p>In most people with MMN, the effect of IVIg only lasts for a few weeks, and maintenance treatment with periodic IVIg infusions for extended periods of time is often indicated (<a href="./references#CD004429-bbs2-0032" title="AzulayJP , RihetP , PougetJ , CadorF , BlinO , BoucrautJ , et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. Journal of Neurology, Neurosurgery and Psychiatry1997;62(4):391-4.">Azulay 1997</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0076" title="MeucciN , CappellariA , BarbieriS , ScarlatoG , Nobile-OrazioE . Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1997;63(6):765-9.">Meucci 1997</a>; <a href="./references#CD004429-bbs2-0108" title="Van den BergLH , FranssenH , WokkeJH . The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain1998;121(Pt 3):421-8.">Van den Berg 1998</a>; <a href="./references#CD004429-bbs2-0028" title="Van den Berg-VosRM , FranssenH , WokkeJH , Van den BergLH . Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain2002;125(Pt 8):1875-86. ">Van den Berg‐Vos 2002</a>). Maintenance treatment regimens range from 0.4 g/kg once a week to 1 to 2 g/kg given over two or five days monthly, or are guided by individual response. If initial treatment with IVIg is effective, IVIg maintenance therapy appears to remain effective in most patients. However, the effectiveness usually declines during prolonged treatment, requiring increasing dose or higher frequency of administration, or both (<a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>; <a href="./references#CD004429-bbs2-0104" title="TerenghiF , CappellariA , BersanoA , CarpoM , BarbieriS , Nobile-OrazioE . How long is IVIg effective in multifocal motor neuropathy?Neurology2004;62(4):666-8.">Terenghi 2004</a>; <a href="./references#CD004429-bbs2-0028" title="Van den Berg-VosRM , FranssenH , WokkeJH , Van den BergLH . Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain2002;125(Pt 8):1875-86. ">Van den Berg‐Vos 2002</a>). This long‐term decline in effectiveness is probably due to ongoing axonal degeneration, which is reflected in progressive reduction of CMAP amplitudes and decreased muscle strength (<a href="./references#CD004429-bbs2-0104" title="TerenghiF , CappellariA , BersanoA , CarpoM , BarbieriS , Nobile-OrazioE . How long is IVIg effective in multifocal motor neuropathy?Neurology2004;62(4):666-8.">Terenghi 2004</a>; <a href="./references#CD004429-bbs2-0108" title="Van den BergLH , FranssenH , WokkeJH . The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain1998;121(Pt 3):421-8.">Van den Berg 1998</a>). In a published retrospective study, treatment with higher‐than‐normal maintenance doses of IVIg promoted reinnervation, decreased the number of conduction blocks, and prevented axonal degeneration in 10 people with MMN up to 12 years (<a href="./references#CD004429-bbs2-0115" title="VucicS , BlackKR , ChongPST , CrosD . Multifocal motor neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIg. Neurology2004;63(7):1264-9.">Vucic 2004</a>). </p> <p>The need for ongoing IVIg treatment in most people with MMN is accompanied by the burden of frequent infusions, adverse effects in some people, and high healthcare costs. SCIg, which has the main advantage of self‐infusion not requiring admission to hospital, could be an alternative treatment to IVIg. This route of administration increases an individual's autonomy and possibly quality of life (<a href="./references#CD004429-bbs2-0038" title="CocitoD , MerolaA , PeciE , MazzeoA , FazioR , FranciaA , et al. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. Journal of Neurology2014;261(11):2159-64.">Cocito 2014</a>). In general, maintenance treatment with SCIg is administered once or twice per week, depending on the required dose, local adverse events, and the patient's preference. IVIg and SCIg dose and interval are titrated individually to find the lowest possible dose to prevent deterioration. Infusions can take place at hospitals, infusion centres, or at home when administered by specialised nurses. </p> <p>Periodic IVIg and SCIg withdrawals are recommended to determine immunoglobulin dependency and to establish the lowest effective concentration. Whether and when IVIg or SCIg withdrawals should be attempted in people with MMN is unknown. In the largest retrospective study including 88 people with MMN, four (5%) IVIg responders did not require ongoing treatment (<a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>). In another study of 40 participants, IVIg withdrawal was possible in 22% (<a href="./references#CD004429-bbs2-0023" title="LégerJM , VialaK , CancalonF , MaisonobeT , GruwezB , WaegemansT , et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. Journal of Neurology, Neurosurgery and Psychiatry2008;79(1):93-6. ">Léger 2008</a>). </p> </section> <section id="CD004429-sec-0012"> <h3 class="title" id="CD004429-sec-0012">How the intervention might work</h3> <p>The ways by which immunoglobulin exerts its supposed beneficial effect in MMN are not clear, but various mechanisms have been suggested (<a href="./references#CD004429-bbs2-0065" title="KazatchkineMD , KaveriSV . Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine2001;345(10):747-55.">Kazatchkine 2001</a>; <a href="./references#CD004429-bbs2-0112" title="Van SchaikIN , VermeulenM , BrandA . In vitro effects of polyvalent immunoglobulin for intravenous use. Journal of Neurology, Neurosurgery and Psychiatry1994;57(Suppl):15-7.">Van Schaik 1994</a>; <a href="./references#CD004429-bbs2-0119" title="YuZ , LennonVA . Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New England Journal of Medicine1999;340(3):227-8.">Yu 1999</a>). Studies in other diseases treated with IVIg have demonstrated that IVIg may inhibit auto‐antibody production, neutralise pathogenic antibodies, decrease antibody‐dependent cellular cytotoxicity by blocking Fc‐receptors on macrophages, and prevent differentiation of B‐cells to IgG producing plasma cells by restoring expression of inhibitory FcRII receptors on B‐cells (<a href="./references#CD004429-bbs2-0065" title="KazatchkineMD , KaveriSV . Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine2001;345(10):747-55.">Kazatchkine 2001</a>). Furthermore, peripheral blood from people with MMN who have been treated with IVIg shows increased CD8‐positive suppressor T‐cell function (<a href="./references#CD004429-bbs2-0044" title="DelfraissyJF , TcherniaG , LaurianY , WallonC , GalanaudP , DormontJ . Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. British Journal of Haematology1985;60(2):315-22.">Delfraissy 1985</a>; <a href="./references#CD004429-bbs2-0069" title="LeungDYM , BurnsJC , NewburgerJW , GehaRS . Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. Journal of Clinical Investigation1987;79(2):468-72.">Leung 1987</a>; <a href="./references#CD004429-bbs2-0072" title="MaceyMG , NewlandAC . CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. British Journal of Haematology1990;76(4):513-20.">Macey 1990</a>). The most recent evidence suggests that IVIg inhibits complement activation mediated by anti‐GM1 IgM antibodies in a dose‐dependent fashion (<a href="./references#CD004429-bbs2-0094" title="PiepersS , vanden Berg-VosR , van derPolWL , FranssenH , WokkeJ , vanden BergL . Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain2007;130(Pt 8):2004-10.">Piepers 2007</a>; <a href="./references#CD004429-bbs2-0120" title="YukiN , WatanabeH , NakajimaT , SpäthPJ . IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. Journal of Neurology Neurosurgery and Psychiatry2011;82(1):87-91.">Yuki 2011</a>). </p> </section> <section id="CD004429-sec-0013"> <h3 class="title" id="CD004429-sec-0013">Why it is important to do this review</h3> <p>Treatment options for people with MMN are few. In contrast to the response in people with CIDP, people with MMN usually do not respond to steroids or plasma exchange, and may worsen when they receive these treatments (<a href="./references#CD004429-bbs2-0082" title="Nobile-OrazioE . Multifocal motor neuropathy. Journal of Neuroimmunology2001;115(1-2):4-18.">Nobile‐Orazio 2001</a>). Previous studies have shown that adding mycophenolate mofetil, rituximab, and eculizumab did not lead to a significant reduction of the required maintenance IVIg dose (<a href="./references#CD004429-bbs2-0037" title="ChaudhryV , CornblathDR . An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy. Journal of the Peripheral Nervous System2010;15(3):196-201.">Chaudhry 2010</a>; <a href="./references#CD004429-bbs2-0049" title="FitzpatrickAM , MannCA , BarryS , BrennanK , OverellJR , WillisonHJ . An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System2011;16(2):84-91.">Fitzpatrick 2011</a>; <a href="./references#CD004429-bbs2-0094" title="PiepersS , vanden Berg-VosR , van derPolWL , FranssenH , WokkeJ , vanden BergL . Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain2007;130(Pt 8):2004-10.">Piepers 2007</a>). Cyclophosphamide has serious long‐term side effects (<a href="./references#CD004429-bbs2-0076" title="MeucciN , CappellariA , BarbieriS , ScarlatoG , Nobile-OrazioE . Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. Journal of Neurology, Neurosurgery and Psychiatry1997;63(6):765-9.">Meucci 1997</a>), and interferon‐beta 1a has only been tested in very limited numbers of people with MMN (<a href="./references#CD004429-bbs2-0109" title="Van den Berg-VosRM , FranssenH , WokkeJHJ , Van EsHW , Van den BergLH . Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology2000;48(6):919-26.">Van den Berg‐Vos 2000a</a>). At the time of the first version of this Cochrane Review in 2005, four randomised controlled double‐blind trials of IVIg for treating MMN were known to have been performed (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>), but no systematic review had been published. Two more eligible studies have subsequently been published. We have provided a systematic review of the randomised trials of immunoglobulin that have been undertaken in MMN. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004429-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004429-sec-0014"></div> <p>To assess the efficacy and safety of intravenous and subcutaneous immunoglobulin in people with multifocal motor neuropathy (MMN). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004429-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004429-sec-0015"></div> <section id="CD004429-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004429-sec-0017"> <h4 class="title">Types of studies</h4> <p>We searched for all randomised controlled trials (RCTs) or quasi‐RCTs (i.e. trials that are not truly randomised but use alteration or another systematic method of allocation) examining the effects of IVIg and SCIg treatment in people with MMN. We considered quasi‐RCTs in spite of their higher risk of selection bias, because there is a paucity of evidence on this topic. We included two different types of studies dependent on the treatment status of the participants at study entry (baseline): a) studies with immunoglobulin‐naive participants (induction treatment) and b) studies with participants already on maintenance IVIg and SCIg treatment (i.e. immunoglobulin controlled‐withdrawal studies using placebo or alternative treatments to substitute immunoglobulin maintenance treatment). Randomised cross‐over trials were eligible. </p> <p>We included studies regardless of publication status and language of publication.</p> </section> <section id="CD004429-sec-0018"> <h4 class="title">Types of participants</h4> <p>Eligible studies had to include unselected participants with definite or probable MMN according to published criteria (<a href="./references#CD004429-bbs2-0088" title="OlneyRK , LewisRA , PutnamTD , CampelloneJVJ . Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle &amp; Nerve2003;27(1):117-21.">Olney 2003</a>; <a href="./references#CD004429-bbs2-0109" title="Van den Berg-VosRM , FranssenH , WokkeJHJ , Van EsHW , Van den BergLH . Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Annals of Neurology2000;48(6):919-26.">Van den Berg‐Vos 2000a</a>; <a href="./references#CD004429-bbs2-0114" title="Van SchaikIN , BoucheP , IllaI , LégerJM , Van den BerghP , CornblathDR , et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Journal of the Peripheral Nervous System2010;15(4):295-301. [DOI: 10.1111/j.1529-8027.2010.00290.x.] [PMID: PMID: 21199100]">Van Schaik 2010</a>). If fulfilment of published criteria were not stated, we defined MMN as a slowly or stepwise progressive asymmetric lower motor neuron syndrome with no bulbar or upper motor signs and evidence of definite or probable conduction block in motor nerves. Mild sensory symptoms at time of diagnosis were permitted as long as there were no sensory signs on examination and sensory nerve conduction studies were normal. People with upper motor neuron features or bulbar signs had to be excluded. Other related conditions, such as other neuropathies (diabetic, lead, porphyric, or vasculitic neuropathy, CIDP, Lyme neuroborreliosis, postradiation neuropathy, hereditary neuropathy with liability to pressure palsies, Charcot‐Marie‐Tooth disease, or paraproteinaemic neuropathies) and myopathies (facioscapulohumeral muscular dystrophy, inclusion body myositis) had to be excluded. </p> </section> <section id="CD004429-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We considered for inclusion studies of any dose of immunoglobulin compared with placebo or any other treatment. All brands of immunoglobulin were included, provided that the preparation was produced according to World Health Organization (WHO) guidelines (<a href="./references#CD004429-bbs2-0116" title="World Health Organization. Appropriate uses of human immunoglobulin in clinical practice: memorandums from a IUIS/WHO meeting. Bulletin of the World Health Organization1982;60:43-7.">WHO 1982</a>). </p> </section> <section id="CD004429-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>In this update we added three secondary outcomes which permitted us to include studies focusing on the ongoing need for immunoglobulin maintenance treatment and studies exploring alternatives to maintenance intravenous immunoglobulin (IVIg) treatment, namely subcutaneous immunoglobulin (SCIg). See <a href="#CD004429-sec-0126">Differences between protocol and review</a>. </p> <p>Eligible studies had to have measured at least one of our efficacy outcomes, but in practice we did not exclude any studies on this basis. </p> <section id="CD004429-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004429-list-0002"> <li> <p>Proportion of participants with an improvement in disability between two and six weeks after the last treatment as determined and defined by the study authors and compared to baseline. </p> </li> </ul> </p> <p>Only studies with immunoglobulin‐naive participants at baseline were eligible for the primary outcome. We defined the primary outcome measure as a proportion because the studies used different disability scales. Each study used the strictest available criteria to define improvement. As immunoglobulin is thought to induce and maintain improvement in the majority of people with MMN, but does not eradicate the disease, people with MMN have to be treated with periodic infusions for long periods. Outcome assessment between two and six weeks after the last IVIg treatment probably reflects the treatment responses of these people best. This period was also used for SCIg. </p> </section> <section id="CD004429-sec-0022"> <h5 class="title">Secondary outcomes</h5> <section id="CD004429-sec-0023"> <h6 class="title">Induction treatment</h6> <p>We assessed these secondary outcomes only for studies with IVIg‐naive participants at baseline (induction treatment). </p> <p> <ul id="CD004429-list-0003"> <li> <p>Proportion of participants with an improvement in muscle strength as determined and defined by the study authors, assessed between two and six weeks after the last treatment and compared to baseline. </p> </li> <li> <p>Mean change in muscle strength expressed as standardised mean difference (SMD), assessed between two and six weeks after the last treatment and compared to baseline in immunoglobulin‐naive participants at study entry. </p> </li> <li> <p>Proportion of participants with a sustained improvement in disability at 12 months or later as determined and defined by the study authors. </p> </li> <li> <p>Proportion of participants in whom at least one conduction block resolved after therapy, assessed between two and six weeks after the last treatment and compared to baseline. </p> </li> </ul> </p> </section> <section id="CD004429-sec-0024"> <h6 class="title">Maintenance treatment</h6> <p>We assessed these secondary outcomes only for studies with participants already receiving IVIg/SCIg at baseline (maintenance treatment). </p> <p> <ul id="CD004429-list-0004"> <li> <p>Proportion of immunoglobulin‐treated participants with an increase in disability during controlled IVIg/SCIg withdrawal as determined and defined by the study authors. </p> </li> <li> <p>Proportion of immunoglobulin‐treated participants with a decrease in muscle strength during controlled IVIg/SCIg withdrawal as determined and defined by the study authors. </p> </li> <li> <p>Mean change in muscle strength expressed as SMD, assessed between two and six weeks after the last treatment and compared to baseline in participants on maintenance IVIg/SCIg treatment at study entry. </p> </li> </ul> </p> </section> <section id="CD004429-sec-0025"> <h6 class="title">Induction or maintenance treatment</h6> <p>We assessed the frequency of adverse effects for all types of studies.</p> <p> <ul id="CD004429-list-0005"> <li> <p>Frequency of adverse effects attributable to treatment during the whole study period.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD004429-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004429-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 20 April 2021.</p> <p> <ul id="CD004429-list-0006"> <li> <p>Cochrane Neuromuscular Specialised Register (in the Cochrane Register of Studies Web;<i> </i><a href="./appendices#CD004429-sec-0113">Appendix 1</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; Issue 4, 2021) (in the Cochrane Register of Studies Web;<i> </i><a href="./appendices#CD004429-sec-0114">Appendix 2</a>) </p> </li> <li> <p>MEDLINE (1946 to 19 April 2021; <a href="./appendices#CD004429-sec-0115">Appendix 3</a>) </p> </li> <li> <p>Embase (1974 to 2021 week 15; <a href="./appendices#CD004429-sec-0116">Appendix 4</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (https://trialsearch.who.int/ ; <a href="./appendices#CD004429-sec-0117">Appendix 5</a>) </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="./appendices#CD004429-sec-0118">Appendix 6</a>) </p> </li> </ul> </p> </section> <section id="CD004429-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We searched the references listed in the published studies, reviews, textbooks, and relevant conference proceedings. We contacted investigators known as active in the field to identify unpublished or overlooked studies. We invite readers to suggest studies, particularly in other languages, that we should consider for inclusion when the review is updated. </p> </section> </section> <section id="CD004429-sec-0029"> <h3 class="title" id="CD004429-sec-0029">Data collection and analysis</h3> <section id="CD004429-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (IvS and LvdB for the first version of the review, and FE and IvS or FE and SK for the 2021 update) independently reviewed the titles and abstracts obtained from the literature searches for potential relevance. We obtained the full‐text reports of those studies deemed potentially relevant, and the review authors selected trials for inclusion in the review. Review authors were not blinded to author and source institution. Any disagreements were resolved by consensus. The review authors recorded the study selection process in sufficient detail to create a PRISMA flow diagram and <a href="./references#CD004429-sec-0129" title="">Characteristics of excluded studies</a> tables (<a href="./references#CD004429-bbs2-0077" title="MoherD , ShamseerL ,  Clarke M, GhersiD , LiberatiA , PetticrewM , et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews2015;4:1. [DOI: 10.1186/2046-4053-4-1.]">Moher 2015</a>). </p> </section> <section id="CD004429-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SK and RB) independently extracted outcome data from newly identified trials using a data extraction tool. Both review authors entered data into Review Manager 5 (<a href="./references#CD004429-bbs2-0098" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), with any disagreements resolved by consensus.  </p> <p>For this update, one review author (SK) extracted data for the following characteristics: study design, eligibility criteria, date conducted, setting, participant characteristics, intervention detail, outcomes assessed, conflicts of interest amongst investigators, funding sources, and potentially relevant studies in references, and entered these data into Review Manager 5 (<a href="./references#CD004429-bbs2-0098" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). There were two new studies at this update; piloting the data extraction form was not feasible.  </p> <p>For studies requiring translation, we would extract data from a translation of the study. We would cross‐check numerical data from translated studies with the study report if possible. </p> </section> <section id="CD004429-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We completed a risk of bias table addressing the following domains: sequence generation, allocation concealment, blinding of participants and personnel (performance bias), blinding of outcome assessors (detection bias), incomplete outcome data, selective outcome reporting, and other sources of bias (e.g. biases arising from the cross‐over design of the included studies), according to the guidance in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004429-bbs2-0055" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). Two review authors (RB and SK) independently completed risk of bias assessments, making a judgement of low, high, or unclear risk of bias for each domain. Any differences were resolved by discussion. The review authors considered risk of bias judgements for each outcome across domains when making GRADE assessments (see below). </p> </section> <section id="CD004429-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (the proportion of participants with an improvement in disability, proportion of participants with an improvement of muscle strength, proportion of participants with an improvement in disability at 12 months, proportion of participants in which at least one conduction block resolved after therapy, proportion of immunoglobulin‐treated participants with an increase in disability during controlled IVIg/SCIg withdrawal, proportion of immunoglobulin‐treated participants with a decrease in muscle strength during controlled IVIg/SCIg withdrawal, and frequency of adverse effects attributable to treatment during the whole study period), we calculated the risk ratio (RR) with corresponding 95% confidence intervals (CIs) for each study. </p> <p>Regarding continuous data (changes in muscle strength in immunoglobulin‐naive participants and changes in muscle strength in participants on maintenance IVIg/SCIg treatment), we anticipated that different trials would use different scales to assess muscle strength. We calculated effect sizes for each study and pooled them using SMD, as muscle strength assessment was not sufficiently comparable between studies to allow for analysis with mean differences. The SMD is a dimensionless measure of effect for continuous data, which is useful for combining results of individual studies in which the same outcome is measured with different instruments or scales. The SMD is defined as the mean change in score of the placebo group minus mean change in score of the treatment group, divided by the pooled standard deviation (SD) of the change in scores of the two groups. We derived means, SDs, and standard errors by calculation or extraction from the available data. If reports provided only CIs, we calculated SDs using values specific to the distribution given the expected small sample sizes of the study (<a href="./references#CD004429-bbs2-0042" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>). </p> </section> <section id="CD004429-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>If there were insufficient data to allow paired analysis in cross‐over trials, we considered cross‐over trials as single parallel‐design trials, assuming that the groups from both parts of the cross‐over trial were independent, rather than as a single group of participants, and assuming that no carry‐over effect had occurred. We intended to include data from participants who did not cross over to the second treatment for the first treatment only. If multiple trial arms were reported in a single trial, we would include only the treatment arms relevant to the review topic. If two intervention groups in the same meta‐analysis had a shared comparison group (e.g. drug A versus placebo and drug B versus placebo), we would follow the guidance in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to avoid double‐counting (<a href="./references#CD004429-bbs2-0056" title="HigginsJPT , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD004429-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>We obtained individual participant data for one study (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). There were no other missing data. </p> </section> <section id="CD004429-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity amongst the trials in each analysis (<a href="./references#CD004429-bbs2-0054" title="HigginsJPT , ThompsonSG , DeeksJD , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). If we identified substantial unexplained heterogeneity, we reported it and examined trial characteristics for likely causes. We used the rough guide to interpretation of I² as outlined in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004429-bbs2-0042" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>), as follows: </p> <p> <ul id="CD004429-list-0007"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>We avoided the use of absolute cut‐off values, instead interpreting I² in relation to the size and direction of effects and strength of evidence for heterogeneity (e.g. P value from the Chi² test, or CI for I²) (<a href="./references#CD004429-bbs2-0042" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Deeks 2019</a>). </p> </section> <section id="CD004429-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched clinical trials registries for ongoing or completed but unpublished trials to limit publication, citation, location, and outcome reporting bias. There was an insufficient number of studies (at least 10 are required) to create a funnel plot to assess small‐study effects (<a href="./references#CD004429-bbs2-0089" title="PageMJ , HigginsJPT , SterneJAC . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Page 2019</a>). </p> </section> <section id="CD004429-sec-0038"> <h4 class="title">Data synthesis</h4> <p>When in interpreting the I², the size and direction of effects and strength of evidence for heterogeneity showed data to be heterogeneous, we used the random‐effects model of DerSimonian and Laird (<a href="./references#CD004429-bbs2-0059" title="IoannidisJPA , CappelleriJC , LauJ , SkolnikPR , MelvilleB , ChalmersTC , et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Annals of Internal Medicine1995;122(11):856-66.">Ioannidis 1995</a>), employing Review Manager 5 (<a href="./references#CD004429-bbs2-0098" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). If no heterogeneity could be demonstrated, we used a fixed‐effect model (Mantel‐Haenszel RR method) (<a href="./references#CD004429-bbs2-0100" title="RothmanKJ . Modern Epidemiology. Boston: Little, Brown and Company, 1986.">Rothman 1986</a>). To assess overall efficacy on proportional outcomes from all the studies, we calculated pooled RR estimates. We obtained absolute risk differences using Review Manager 5 analyses. For continuous data, we pooled individual SMDs with the generic inverse variance method available in Review Manager 5. In this method, 1/variance is used as weights. We expressed statistical uncertainty with 95% CI. We analysed data from studies exploring alternative treatments to maintenance IVIg treatment in a separate comparison (IVIg versus SCIg) and analysed induction studies and maintenance studies separately, other than for adverse events, for which we pooled the data from both types of study. </p> </section> <section id="CD004429-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If there was heterogeneity, we investigated possible sources by repeating the analysis after elimination of trials at high or unclear risk of bias, paying particular attention to allocation concealment. </p> <p>We did not plan subgroup analyses, given the likely size of included studies in this rare disease. </p> </section> <section id="CD004429-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>In the original protocol, we stated that sensitivity analysis was to be performed only in the presence of heterogeneity, in which case the source was to be investigated by repeating the analysis after elimination of trials that scored less than A (adequate) on each of the indices of quality then in use, paying particular attention to allocation concealment. For the review update, we planned the following sensitivity analyses: </p> <p> <ul id="CD004429-list-0008"> <li> <p>repeat the analysis excluding unpublished studies;</p> </li> <li> <p>repeat the analysis excluding studies at high risk of bias in the event of heterogeneity.</p> </li> </ul> </p> <p>The protocol also specified an intention to assess the effect of including cross‐over studies; however, all of the included studies had a cross‐over design. </p> <p>We performed a sensitivity analysis excluding <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>, as the validity of the trial design was debatable (see <a href="#CD004429-sec-0053">Included studies</a> for details). This was the only sensitivity analysis, as there was no statistical heterogeneity, and all studies were published.  </p> <p>We reviewed open and uncontrolled studies and compared them to the results of the included studies in the <a href="#CD004429-sec-0091">Discussion</a>. We discussed adverse events of IVIg from the non‐randomised literature in relation to the adverse events found in this review in the <a href="#CD004429-sec-0091">Discussion</a>. </p> </section> <section id="CD004429-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created summary of findings tables using GRADEpro GDT software (<a href="./references#CD004429-bbs2-0052" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 20 October 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>), and presented the following outcomes: </p> <section id="CD004429-sec-0042"> <h5 class="title">For the comparison IVIg/SCIg compared to placebo for MMN</h5> <section id="CD004429-sec-0043"> <h6 class="title">Primary outcome</h6> <p> <ul id="CD004429-list-0009"> <li> <p>Proportion of participants with an improvement in disability as determined and defined by the study authors, assessed between two and six weeks after the last treatment, compared to baseline. </p> </li> </ul> </p> </section> <section id="CD004429-sec-0044"> <h6 class="title">Secondary outcomes</h6> <section id="CD004429-sec-0045"> <p><b>Induction treatment</b></p> <p> <ul id="CD004429-list-0010"> <li> <p>Proportion of participants with an improvement of muscle strength as determined and defined by the study authors, assessed between two and six weeks after the last treatment and compared to baseline. </p> </li> <li> <p>Proportion of participants with an improvement in disability at 12 months or later as determined and defined by the study authors. </p> </li> <li> <p>Proportion of participants in whom at least one conduction block resolved after therapy, assessed between two and six weeks after the last treatment and compared to baseline. </p> </li> </ul> </p> </section> <section id="CD004429-sec-0046"> <p><b>Maintenance treatment</b></p> <p> <ul id="CD004429-list-0011"> <li> <p>Proportion of IVIg/SCIg‐treated participants with an increase in disability during controlled immunoglobulin withdrawal as determined and defined by the study authors. </p> </li> <li> <p>Proportion of IVIg/SCIg‐treated participants with a decrease in muscle strength during controlled immunoglobulin withdrawal as determined and defined by the study authors. </p> </li> </ul> </p> </section> <section id="CD004429-sec-0047"> <p><b>Induction or maintenance treatment</b></p> <p> <ul id="CD004429-list-0012"> <li> <p>Frequency of adverse effects attributable to treatment during the whole study period.</p> </li> </ul> </p> </section> </section> </section> <section id="CD004429-sec-0048"> <h5 class="title">For the comparison IVIg compared to SCIg for MMN</h5> <p>This comparison was not applicable to induction treatment.</p> <section id="CD004429-sec-0049"> <h6 class="title">Outcomes</h6> <p> <ul id="CD004429-list-0013"> <li> <p>Proportion of IVIg/SCIg‐treated participants with an increase in disability during controlled immunoglobulin withdrawal as determined and defined by the study authors. </p> </li> <li> <p>Proportion of IVIg/SCIg‐treated participants with a decrease in muscle strength during controlled immunoglobulin withdrawal as determined and defined by the study authors. </p> </li> <li> <p>Frequency of adverse effects attributable to treatment during the whole study period.</p> </li> </ul> </p> <p>Two review authors (FE and IvS) used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to independently assess the certainty of a body of evidence (i.e. studies that contribute data for the prespecified outcomes). We used the methods and recommendations described in Chapters 14 and 15 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004429-bbs2-0101" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019a</a>; <a href="./references#CD004429-bbs2-0102" title="SchünemannHJ , VistGE , HigginsJPT , SantessoN , DeeksJJ , GlasziouP , AklEA , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Schünemann 2019b</a>). Any disagreements were resolved by discussion or by involving another review author (LvdB). We assessed trial quality according to the GRADE criteria. We considered RCTs as high‐certainty evidence if the above five factors were not present to any serious degree, downgrading the certainty to moderate, low, or very low as required. We downgraded the certainty of the evidence once if a GRADE consideration was serious and twice if very serious. We justified all decisions to down‐ or upgrade the certainty of the evidence using footnotes and made comments to aid the reader's understanding of the review where necessary. </p> <p>We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. The recommendations for practice and our implications for research suggest priorities for future research and outline the remaining uncertainties in the area. We assessed the certainty of the evidence and stated uncertainties. </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004429-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004429-sec-0050"></div> <section id="CD004429-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD004429-sec-0052"> <h4 class="title">Results of the search</h4> <p>A flow chart illustrating the study selection process is provided in <a href="#CD004429-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD004429-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study selection flow chart." data-id="CD004429-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study selection flow chart.</p> </div> </div> </div> <p>The previous version of the review included four studies (<a href="./references#CD004429-bbs2-0122" title="Van SchaikIN , Van den BergLH , De HaanR , VermeulenM . Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD004429. [DOI: 10.1002/14651858.CD004429.pub2]">Van Schaik 2005</a>). </p> <p>For this update, our database searches retrieved 451 references. After removal of 149 duplicates, we screened 302 records. From these, we identified 28 reports, from which we selected two new included studies (eight associated references) and excluded 11 studies (20 associated references). We identified no ongoing studies or studies awaiting classification. </p> <p>In total, six RCTs (13 reports) from the previous version of the review and this update were eligible for inclusion (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>; <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). </p> <p>We excluded 23 studies (<a href="./references#CD004429-bbs2-0007" title="Al-ZuhairyA , JakobsenJ , AndersenH , SindrupSH , MarkvardsenLH . Facilitated subcutaneous immunoglobulin in multifocal motor neuropathy - a randomized, single-blinded, noninferiority cross-over trial. European Journal of Neurology2019;26(S1):71. Al-ZuhairyA , JakobsenJ , AndersenH , SindrupSH , MarkvardsenLK . Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy. European Journal of Neurology2019;26(10):1289-e82. EUCTR2015-003453-18-DK. Study of the effect and safety of a new immunoglobulin preparation (HyQvia) for subcutaneous usage in patients with multifocal motor neuropathy. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-003453-18-DK (first received 23 September 2015). NCT02556437. Efficacy and safety of HyQvia (Immunoglobulin 10% with recombinant hyaluronidase) in multifocal motor neuropathy (MMN). clinicaltrials.gov/ct2/show/NCT02556437 (first received 22 September 2015). ">Al‐Zuhairy 2019</a>; <a href="./references#CD004429-bbs2-0008" title="AuerRN . Multifocal motor neuropathy. Annals of Neurology1994;35(2):246-7. ">Auer 1994</a>; <a href="./references#CD004429-bbs2-0009" title="BaumannA , HessCW , SturzeneggerM . IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. Journal of Neurology2009;256(4):608-14. ">Baumann 2009</a>; <a href="./references#CD004429-bbs2-0010" title="BurrellJR , YiannikasC , RoweD , KiernanMC . Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS ONE2011;6:e27041. ">Burrell 2011</a>; <a href="./references#CD004429-bbs2-0011" title="CatsEA , van derPolWL , PiepersS , NotermansNC , vanden Berg-VosRM , vanden BergLH . New liquid intravenous immunoglobulin (10% IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability. Journal of Neurology2008;255(10):1598-9. ">Cats 2008</a>; <a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>; <a href="./references#CD004429-bbs2-0013" title="CharlesN , BenoitP , VialC , BiermeT , MoreauT , BadyB . Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet1992;340(8812):182. ">Charles 1992</a>; <a href="./references#CD004429-bbs2-0014" title="EftimovF , VermeulenM , De HaanRJ , Van den BergLH , Van SchaikIN . Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. Journal of the Peripheral Nervous System2009;14(2):93-100. ">Eftimov 2009</a>; <a href="./references#CD004429-bbs2-0015" title="HerraetsIJT , BakersJNE , vanEijkRPA , GoedeeHS , van derPolWL , vanden BergLH . Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. Journal of Neurology2019;266(11):2734-42. [PMID: 31325017]">Herraets 2019</a>; <a href="./references#CD004429-bbs2-0016" title="JafariH , CarlanderB , CamuW . Monofocal motor neuropathy responsive to intravenous immunoglobulins. Muscle &amp; Nerve2000;23(10):1610-11. ">Jafari 2000</a>; <a href="./references#CD004429-bbs2-0017" title="Kelly JJ Jr. Multifocal motor neuropathy. Neurology1992;42(11):2230. ">Kelly 1992</a>; <a href="./references#CD004429-bbs2-0018" title="KermodeAG , LaingBA , CarrollWM , MastagliaFL . Intravenous immunoglobulin for multifocal motor neuropathy. Lancet1992;340(8824):920-1. ">Kermode 1992</a>; <a href="./references#CD004429-bbs2-0019" title="KöllerH , SchroeterM , FeischenH , HartungHP , KieseierBC . Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. Journal of Neurology2006;253(11):1505-6. ">Köller 2006</a>; <a href="./references#CD004429-bbs2-0020" title="KomiyamaA , TodaH , HasegawaO , KuroiwaY . Multifocal motor neuropathy. Neurology1998;50(1):314-5. ">Komiyama 1998</a>; <a href="./references#CD004429-bbs2-0021" title="KuboriT , MezakiT , KajiR , KimuraJ , HamaguchiK , HirayamaK , et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No-to Shinkei [Brain &amp; Nerve]1999;51(2):127-35. ">Kubori 1999</a>; <a href="./references#CD004429-bbs2-0022" title="KuwabaraS , MisawaS , MoriM , IwaiY , OchiK , SuzukiH , et al. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: a multi-center, open-label, 52-week phase 3 trial. Journal of the Peripheral Nervous System2018;23(2):115-9. NCT01827072. Phase III clinical trial of NPB-01 maintenance therapy in patients with multifocal motor neuropathy. clinicaltrials.gov/ct2/show/NCT01827072 (first received 9 April 2018). ">Kuwabara 2018</a>; <a href="./references#CD004429-bbs2-0023" title="LégerJM , VialaK , CancalonF , MaisonobeT , GruwezB , WaegemansT , et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. Journal of Neurology, Neurosurgery and Psychiatry2008;79(1):93-6. ">Léger 2008</a>; <a href="./references#CD004429-bbs2-0024" title="EUCTR2012-01995-12-ES. A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in patients with multifocal motor neuropathy. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001995-12/GB (first received 3 June 2013). LégerJM , Alfa CisséO , CocitoD , GrouinJM , KatifiH , Nobile-OrazioE , et al. IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: a randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig® - The LIME Study. Journal of the Peripheral Nervous System2019;24(1):56-63. LegerJM , HughesR , MerkiesISJ , Nobile-OrazioE ,  MalyszczakW ,  PugetS . A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus KIOVIG in patients with multifocal motor neuropathy. Journal of the Peripheral Nervous System2015;20(2):181. LegerJM , HughesRAC , MerkiesISJ , Nobile-OrazioE , MalyszczakW , PugetS . A European, randomised, double-blind, cross-over study of a new 10% human intravenous immunoglobulin versus other IVIG in patients with multifocal motor neuropathy - LIME study. Journal of the Peripheral Nervous System2016;21(3):189. LegerJM , HughesRAC , MerkiesISJ , Nobile-OrazioE , MalyszczakW , PugetS . European, randomised, double-blind, crossover study of a new 10% human intravenous immunoglobulin versus other IVIG in patients with multifocal motor neuropathy - Lime Study. Journal of the Peripheral Nervous System2016;21:77-8. NCT01951924. LIME Study (LFB IVIg MMN Efficacy Study) (LIME). clinicaltrials.gov/ct2/show/NCT01951924 (first received 27 September 2013). ">Léger 2019</a>; <a href="./references#CD004429-bbs2-0025" title="PestronkA . Immunosuppressive treatment of motor neuron syndromes. Archives of Neurology1995;52(3):230-1. ">Pestronk 1995</a>; <a href="./references#CD004429-bbs2-0026" title="TanE , LynnDJ , AmatoAA , KisselJT , RammohanKW , SahenkZ , et al. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Archives of Neurology1994;51(2):194-200. ">Tan 1994</a>; <a href="./references#CD004429-bbs2-0027" title="TurnbullJ . Multifocal motor neuropathy improved by IVIg. Neurology2001;56(11):1608. ">Turnbull 2001</a>; <a href="./references#CD004429-bbs2-0028" title="Van den Berg-VosRM , FranssenH , WokkeJH , Van den BergLH . Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain2002;125(Pt 8):1875-86. ">Van den Berg‐Vos 2002</a>; <a href="./references#CD004429-bbs2-0029" title="YukiN , YamazakiM . Treatment of multifocal motor neuropathy with a high dosage of intravenous immunoglobulin. Muscle &amp; Nerve1993;16(2):220-1. ">Yuki 1993</a>). See <a href="#CD004429-sec-0060">Excluded studies</a>. </p> </section> <section id="CD004429-sec-0053"> <h4 class="title">Included studies</h4> <section id="CD004429-sec-0054"> <h5 class="title">Participants</h5> <p>Six RCTs including 90 randomised participants with MMN were eligible (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>; <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). </p> <p>Four studies included immunoglobulin‐naive participants at study entry and used IVIg as study treatment; in two of these studies all participants were treatment naive (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>). One study included both treatment‐naive participants and participants previously treated with IVIg (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>), and one study was designed as a proof‐of‐principle study (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>), in which all participants had previously been treated with IVIg. Participants from <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a> who were previously treated with IVIg were not included in our analysis. Although participants in <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> were selected on the basis of IVIg response in an open trial before entering a double‐blind, placebo‐controlled, randomised, cross‐over trial, we decided to include this study because all participants were unselected when entering the open phase of the trial, and all of these participants responded to IVIg, therefore all participants entered the second phase. As the validity of this trial design is debatable, we presented results with and without this study. </p> <p>Two studies included known IVIg responders receiving maintenance IVIg treatment at baseline: one study compared continuation of IVIg with placebo (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>), and the other continuation of IVIg with SCIg (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). </p> </section> <section id="CD004429-sec-0055"> <h5 class="title">Interventions</h5> <p>The included studies used different treatment regimens of total infusion dose and interval between infusions. Three studies used a total of 2 g/kg body weight of IVIg administered over five days (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>), whilst one study used 2.5 g/kg body weight of IVIg over five days (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>). In two studies, IVIg dose and intervals were equal to the individual pre‐study regimen. In one of these studies, mean monthly dose was 1.2 g/kg, with intervals ranging between two and four weeks (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>); in the other study, IVIg dose ranged between 0.6 g/kg and 2.1 g/kg per month, with intervals ranging between 18 and 56 days (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). SCIg dose was equivalent to IVIg dose in individual participants and ranged between 0.2 g/kg and 0.5 g/kg per week (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). The total SCIg amount was administered in two or three doses over the week. </p> </section> <section id="CD004429-sec-0056"> <h5 class="title">Study design</h5> <p>All six RCTs had a cross‐over design. Cross‐over took place eight weeks after the first treatment in one study (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>). In another study, participants crossed over into the second arm at day 28 if they remained unchanged or deteriorated (<a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>). Participants who had improved at day 28 did not enter the second arm until they were back at baseline levels. Léger and colleagues treated participants each month for three months (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>). After three treatments, all participants who were responders remained on the same treatment for three months, and the non‐responders crossed over for the following three months. Van den Berg and colleagues treated participants four times with IVIg or placebo in random order (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). The interval between each treatment was determined by the time it took for the participant to get back to baseline levels, with a minimum of one month. Our prespecified outcomes were assessed at one month after the last IVIg infusion in three studies (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>), and at variable time points ranging between two and four weeks in one study (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). In Hahn and colleagues, participants received pre‐treatment with IVIg for 12 weeks before they entered the first study treatment period of 12 weeks. After the first study period, all participants received open‐label IVIg for 12 weeks ('wash‐out') before entering the second study period of 12 weeks. Participants who deteriorated during the first period were restabilised during the open‐label IVIg period and crossed to the second treatment ('accelerated switch') (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). The study comparing SCIg with IVIg was preceded by a prolonged treatment‐free interval of a maximum of 10 weeks to ensure that participants were responsive to immunoglobulins and a restabilisation phase of IVIg infusion (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). Interventions were separated by a variable wash‐out period during which participants received two regular doses of IVIg. </p> </section> <section id="CD004429-sec-0057"> <h5 class="title">Outcomes</h5> <p>Each study used different outcome measures. For details, see <a href="./references#CD004429-sec-0128" title="">Characteristics of included studies</a>. Only individual participant data were obtained from one study (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). </p> </section> <section id="CD004429-sec-0058"> <h5 class="title">Settings</h5> <p>Two studies were conducted in France (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>), one in neuromuscular clinics in Canada (<a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>), one multicentre study in 17 centres in the USA, Canada, and Denmark (with the option of home infusion in the USA and Canada) (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>), one in Denmark (hospital and thereafter home self‐administration) (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>), and one in hospitals in the Netherlands (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). </p> </section> <section id="CD004429-sec-0059"> <h5 class="title">Funding and conflicts of interest</h5> <p>The trial comparing IVIg versus placebo maintenance treatment was sponsored by an IVIg manufacturer; employees were also involved in the study. However, the manuscript was reviewed by independent experts to whom the trial data were made available (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). An additional trial involved authors with conflicts of interest through employment (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>). The remaining trials had no reported commercial funding and were without conflicts of interest, or did not provide this information. </p> </section> </section> <section id="CD004429-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We listed 23 excluded reports or studies. The reasons for exclusion were as follows:</p> <p> <ul id="CD004429-list-0014"> <li> <p>four letters to editor (<a href="./references#CD004429-bbs2-0008" title="AuerRN . Multifocal motor neuropathy. Annals of Neurology1994;35(2):246-7. ">Auer 1994</a>; <a href="./references#CD004429-bbs2-0017" title="Kelly JJ Jr. Multifocal motor neuropathy. Neurology1992;42(11):2230. ">Kelly 1992</a>; <a href="./references#CD004429-bbs2-0025" title="PestronkA . Immunosuppressive treatment of motor neuron syndromes. Archives of Neurology1995;52(3):230-1. ">Pestronk 1995</a>; <a href="./references#CD004429-bbs2-0027" title="TurnbullJ . Multifocal motor neuropathy improved by IVIg. Neurology2001;56(11):1608. ">Turnbull 2001</a>); </p> </li> <li> <p>nine case series or case reports (<a href="./references#CD004429-bbs2-0009" title="BaumannA , HessCW , SturzeneggerM . IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. Journal of Neurology2009;256(4):608-14. ">Baumann 2009</a>; <a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>; <a href="./references#CD004429-bbs2-0013" title="CharlesN , BenoitP , VialC , BiermeT , MoreauT , BadyB . Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet1992;340(8812):182. ">Charles 1992</a>; <a href="./references#CD004429-bbs2-0016" title="JafariH , CarlanderB , CamuW . Monofocal motor neuropathy responsive to intravenous immunoglobulins. Muscle &amp; Nerve2000;23(10):1610-11. ">Jafari 2000</a>; <a href="./references#CD004429-bbs2-0018" title="KermodeAG , LaingBA , CarrollWM , MastagliaFL . Intravenous immunoglobulin for multifocal motor neuropathy. Lancet1992;340(8824):920-1. ">Kermode 1992</a>; <a href="./references#CD004429-bbs2-0019" title="KöllerH , SchroeterM , FeischenH , HartungHP , KieseierBC . Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. Journal of Neurology2006;253(11):1505-6. ">Köller 2006</a>; <a href="./references#CD004429-bbs2-0020" title="KomiyamaA , TodaH , HasegawaO , KuroiwaY . Multifocal motor neuropathy. Neurology1998;50(1):314-5. ">Komiyama 1998</a>; <a href="./references#CD004429-bbs2-0023" title="LégerJM , VialaK , CancalonF , MaisonobeT , GruwezB , WaegemansT , et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. Journal of Neurology, Neurosurgery and Psychiatry2008;79(1):93-6. ">Léger 2008</a>; <a href="./references#CD004429-bbs2-0029" title="YukiN , YamazakiM . Treatment of multifocal motor neuropathy with a high dosage of intravenous immunoglobulin. Muscle &amp; Nerve1993;16(2):220-1. ">Yuki 1993</a>); </p> </li> <li> <p>seven non‐randomised prospective studies (<a href="./references#CD004429-bbs2-0010" title="BurrellJR , YiannikasC , RoweD , KiernanMC . Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS ONE2011;6:e27041. ">Burrell 2011</a>; <a href="./references#CD004429-bbs2-0011" title="CatsEA , van derPolWL , PiepersS , NotermansNC , vanden Berg-VosRM , vanden BergLH . New liquid intravenous immunoglobulin (10% IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability. Journal of Neurology2008;255(10):1598-9. ">Cats 2008</a>; <a href="./references#CD004429-bbs2-0014" title="EftimovF , VermeulenM , De HaanRJ , Van den BergLH , Van SchaikIN . Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. Journal of the Peripheral Nervous System2009;14(2):93-100. ">Eftimov 2009</a>; <a href="./references#CD004429-bbs2-0015" title="HerraetsIJT , BakersJNE , vanEijkRPA , GoedeeHS , van derPolWL , vanden BergLH . Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. Journal of Neurology2019;266(11):2734-42. [PMID: 31325017]">Herraets 2019</a>; <a href="./references#CD004429-bbs2-0021" title="KuboriT , MezakiT , KajiR , KimuraJ , HamaguchiK , HirayamaK , et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No-to Shinkei [Brain &amp; Nerve]1999;51(2):127-35. ">Kubori 1999</a>; <a href="./references#CD004429-bbs2-0022" title="KuwabaraS , MisawaS , MoriM , IwaiY , OchiK , SuzukiH , et al. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: a multi-center, open-label, 52-week phase 3 trial. Journal of the Peripheral Nervous System2018;23(2):115-9. NCT01827072. Phase III clinical trial of NPB-01 maintenance therapy in patients with multifocal motor neuropathy. clinicaltrials.gov/ct2/show/NCT01827072 (first received 9 April 2018). ">Kuwabara 2018</a>; <a href="./references#CD004429-bbs2-0028" title="Van den Berg-VosRM , FranssenH , WokkeJH , Van den BergLH . Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain2002;125(Pt 8):1875-86. ">Van den Berg‐Vos 2002</a>); </p> </li> <li> <p>one review (<a href="./references#CD004429-bbs2-0026" title="TanE , LynnDJ , AmatoAA , KisselJT , RammohanKW , SahenkZ , et al. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder. Archives of Neurology1994;51(2):194-200. ">Tan 1994</a>); </p> </li> <li> <p>two non‐inferiority RCTs comparing IVIg brands (<a href="./references#CD004429-bbs2-0007" title="Al-ZuhairyA , JakobsenJ , AndersenH , SindrupSH , MarkvardsenLH . Facilitated subcutaneous immunoglobulin in multifocal motor neuropathy - a randomized, single-blinded, noninferiority cross-over trial. European Journal of Neurology2019;26(S1):71. Al-ZuhairyA , JakobsenJ , AndersenH , SindrupSH , MarkvardsenLK . Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy. European Journal of Neurology2019;26(10):1289-e82. EUCTR2015-003453-18-DK. Study of the effect and safety of a new immunoglobulin preparation (HyQvia) for subcutaneous usage in patients with multifocal motor neuropathy. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-003453-18-DK (first received 23 September 2015). NCT02556437. Efficacy and safety of HyQvia (Immunoglobulin 10% with recombinant hyaluronidase) in multifocal motor neuropathy (MMN). clinicaltrials.gov/ct2/show/NCT02556437 (first received 22 September 2015). ">Al‐Zuhairy 2019</a>; <a href="./references#CD004429-bbs2-0024" title="EUCTR2012-01995-12-ES. A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in patients with multifocal motor neuropathy. www.clinicaltrialsregister.eu/ctr-search/trial/2012-001995-12/GB (first received 3 June 2013). LégerJM , Alfa CisséO , CocitoD , GrouinJM , KatifiH , Nobile-OrazioE , et al. IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: a randomised, double-blind, multi-center cross-over non-inferiority study vs Kiovig® - The LIME Study. Journal of the Peripheral Nervous System2019;24(1):56-63. LegerJM , HughesR , MerkiesISJ , Nobile-OrazioE ,  MalyszczakW ,  PugetS . A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus KIOVIG in patients with multifocal motor neuropathy. Journal of the Peripheral Nervous System2015;20(2):181. LegerJM , HughesRAC , MerkiesISJ , Nobile-OrazioE , MalyszczakW , PugetS . A European, randomised, double-blind, cross-over study of a new 10% human intravenous immunoglobulin versus other IVIG in patients with multifocal motor neuropathy - LIME study. Journal of the Peripheral Nervous System2016;21(3):189. LegerJM , HughesRAC , MerkiesISJ , Nobile-OrazioE , MalyszczakW , PugetS . European, randomised, double-blind, crossover study of a new 10% human intravenous immunoglobulin versus other IVIG in patients with multifocal motor neuropathy - Lime Study. Journal of the Peripheral Nervous System2016;21:77-8. NCT01951924. LIME Study (LFB IVIg MMN Efficacy Study) (LIME). clinicaltrials.gov/ct2/show/NCT01951924 (first received 27 September 2013). ">Léger 2019</a>). </p> </li> </ul> </p> <p>See <a href="./references#CD004429-sec-0129" title="">Characteristics of excluded studies</a> tables. We listed all studies excluded at full‐text review, as these papers may be of interest given the paucity of evidence on this topic. </p> </section> </section> <section id="CD004429-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias assessments for each trial are presented in <a href="#CD004429-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD004429-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: red (‐) = high risk of bias, yellow (?) = unclear risk of bias, green (+) = low risk of bias." data-id="CD004429-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: red (‐) = high risk of bias, yellow (?) = unclear risk of bias, green (+) = low risk of bias. </p> </div> </div> </div> <p>None of the included trials was at low risk of bias in all domains. Three trials were at high risk of bias in at least one domain (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>; <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). The remaining trials were at unclear risk of bias in at least two domains (<a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). </p> <section id="CD004429-sec-0062"> <h4 class="title">Allocation</h4> <p><a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a> used a random number generator, and the <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a> protocol indicates use of "computer generated pseudo‐random numbers". <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a> described block randomisation by the pharmacist. We judged all three trials as at low risk of bias for random sequence generation. We assessed <a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>, <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>, and <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> as at unclear risk of bias, as insufficient detail was provided on the method of randomisation.  </p> <p><a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a> and <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a> described their method of allocation concealment and was therefore assessed as at low risk of bias. <a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>, <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>, and <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> did not describe allocation concealment and were therefore assessed as at unclear risk of bias for this domain. In <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>, a central pharmacist distributed opaque infusion bags, but measures to conceal allocation were not clear. </p> </section> <section id="CD004429-sec-0063"> <h4 class="title">Blinding</h4> <p>Only <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a> and <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a> were at low risk of both performance and detection bias, as participants, personnel, and outcome assessors were all blinded, and the reports describe methods to maintain blinding. In <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>, participants and assessors were reported as blinded, but as the trial authors did not describe measures to maintain blinding, our judgement was unclear risk for both blinding domains. In <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>, blinding was attempted, but blinding of participants was not maintained, and all participants could correctly name the treatment sequence. We judged this trial as at high risk of bias for blinding of participants and personnel, and unclear risk of bias for blinding of outcome assessment. In <a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>, treatment providers were not blinded, but did not assess participants; we judged the risk of bias as high for blinding of participants and personnel and unclear for blinding of outcome assessment. was at high risk of bias for both performance and detection bias, as participants and personnel were not blinded, and although assessors were blinded, treatment preference could potentially have influenced outcome measures (e.g. muscle strength). </p> </section> <section id="CD004429-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>All of the included studies addressed the occurrence and reasons for incomplete outcome data. We assessed all studies as at low risk of attrition bias, except for <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>, which was judged unclear. </p> </section> <section id="CD004429-sec-0065"> <h4 class="title">Selective reporting</h4> <p>All of the included studies reported all outcomes that had been prespecified in the methods section in the results section. Protocols were not available for most of the studies. We judged all six studies as at low risk of reporting bias. </p> </section> <section id="CD004429-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>All of the included studies were at unclear risk of other bias, except for <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>, which was at high risk. In two studies, all participants had to be immunoglobulin responders (; ). As the main goal of these trials was to determine whether IVIg maintenance was needed (in ) and whether SCIg is as effective and safe as IVIg maintenance treatment (in ), this recruitment bias seems justified. In <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>, participants were treated with IVIg twice during the 'wash‐out' period, which may have led to a considerable carry‐over effect into the SCIg arm, which lasted only three IVIg cycles; this resulted in a judgement of high risk of bias. In <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>, the blinded period lasted 12 weeks, which is relatively short and could have resulted in a carry‐over effect in the placebo arm, as participants had been treated previously with IVIg (wash‐out periods were scheduled prior to study entry and between study periods). However, in clinical practice most people receive IVIg on a monthly basis because of a four‐week duration of effect, so we judged the risk of bias as unclear rather than high. </p> <p>In one trial it was unclear whether participants with MMN had been treated with immunoglobulins in the past (), which may have led to recruitment bias. The wash‐out period was eight weeks in <a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>, possibly leading to a carry‐over effect in participants who switched from active treatment to placebo treatment. In one trial a variable wash‐out period was defined that lasted between 38 and 120 days and may have led to a variable carry‐over effect between participants (). In this study additional (immunomodulatory) treatments were not addressed. One trial used a response‐conditional cross‐over design, meaning that not all participants received both treatments (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>); however, we used first‐period data from this trial. It was unclear from the <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> report whether additional treatments were allowed. We judged these four trials as at unclear risk of bias. </p> </section> </section> <section id="CD004429-sec-0067"> <h3 class="title" id="CD004429-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD004429-tbl-0001"><b>Summary of findings 1</b> IVIg compared to placebo for multifocal motor neuropathy</a>; <a href="./full#CD004429-tbl-0002"><b>Summary of findings 2</b> IVIg compared to SCIg for multifocal motor neuropathy</a> </p> <section id="CD004429-sec-0068"> <h4 class="title">Immunoglobulins versus placebo</h4> <p>See <a href="./full#CD004429-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD004429-sec-0069"> <h5 class="title">Primary outcome</h5> <section id="CD004429-sec-0070"> <h6 class="title">Proportion of participants with an improvement in disability between two and six weeks after the last treatment as determined and defined by the study authors and compared to baseline </h6> <p>Three RCTs summarising the results of 18 participants were suitable for this analysis (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). All of these trials included IVIg as study treatment, and none used SCIg as study treatment.  </p> <p>Different disability scales were used: none of five participants improved on the modified Norris scale after IVIg or placebo (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>); four out of seven participants improved after IVIg and two out of seven after placebo on a self‐evaluation scale scoring five motor activities of daily life, chosen for each participant together with the examiner at baseline (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>); and three out of six participants improved after IVIg on the modified Rankin scale and none after placebo (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>).  </p> <p>Outcomes were assessed at 28 days after onset of treatment (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>), every month up to four or seven months (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>), and every week up to 28 weeks (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). Intravenous immunoglobulin or placebo was each given 18 times. An improvement was reported in seven out of 18 (39%) IVIg treatments and two out of 18 (11%) placebo treatments. A higher proportion of participants improved after IVIg therapy as compared with placebo, with a pooled risk ratio (RR) of 3.00, but confidence intervals (CIs) did not exclude the possibility of no effect (95% CI 0.89 to 10.12; 3 RCTs, 18 participants; low‐certainty evidence). We used a fixed‐effect model, as the studies were of a similar small size, and the study results did not show evidence of heterogeneity (<a href="#CD004429-fig-0003">Figure 3</a>; <a href="./references#CD004429-fig-0007" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD004429-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="IVIg versus placebo. Proportion of participants with an improvement in disability as determined and defined by the study authors. In all forest plots, the 'Total' columns show the number of observations." data-id="CD004429-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>IVIg versus placebo. Proportion of participants with an improvement in disability as determined and defined by the study authors. In all forest plots, the 'Total' columns show the number of observations. </p> </div> </div> </div> <p>As <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> included participants that were already treated, we performed a sensitivity analysis to determine to what degree it affected the results. When analysing this outcome without the study of Van den Berg and colleagues, an improvement was reported in four out of 12 IVIg treatments and spontaneous improvements in two out of 12 placebo treatments. A higher proportion of participants improved after IVIg therapy compared with placebo, with a pooled RR of 2.00, but CIs did not exclude the possibility of an effect in favour of placebo (95% CI 0.53 to 7.60; 2 RCTs, 12 participants). </p> <p>Both comparisons showed wide CIs. Given the small numbers of participants, a clinically relevant effect cannot be confirmed or excluded. </p> </section> </section> <section id="CD004429-sec-0071"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes were assessed at 28 days after the start of treatment (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>), every month up to four or seven months (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>), every week up to 28 weeks (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>), and during the last treatment cycle of the blinded 12‐week period, or earlier in case of deterioration (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). </p> <section id="CD004429-sec-0072"> <h6 class="title">Induction treatment</h6> <section id="CD004429-sec-0073"> <p><b>Proportion of participants with an improvement in muscle strength as determined and defined by the study authors, assessed between two and six weeks after the last treatment and compared to baseline</b></p> <p>Three RCTs involving 27 participants provided data for this outcome and were included in meta‐analysis (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). All three trials used only IVIg as the study treatment. </p> <p>Azulay and colleagues obtained a muscle score by summing the strength assessed in two muscles that had to be impaired and were selected at the beginning of the study. An improvement was defined as an increased muscle score of more than 50% compared to baseline (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>). In this study, five participants improved in muscle strength after IVIg and none after placebo. Van den Berg and colleagues assessed 11 different muscles using a handheld dynamometer. An improvement was defined as an increase of 50% or more in at least two muscles, without a decrease of at least 25% in more than one other muscle (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). In this study, five out of six participants improved after IVIg and one after placebo. Federico and colleagues asked participants to subjectively rate their strength at the end of a treatment period compared to the beginning (<a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>). In this study, 11 out of 16 participants rated their strength as improved after treatment, whereas none of the participants did so after placebo. </p> <p>Overall, an improvement of muscle strength was reported in 21 out of 27 (78%) IVIg treatments and one out of 27 (4%) placebo treatments. A higher proportion of participants improved after IVIg therapy compared with placebo, with a pooled RR of 11.00 (95% CI 2.86 to 42.25; 3 RCTs, 27 participants; low‐certainty evidence; <a href="./references#CD004429-fig-0008" title="">Analysis 1.2</a>). Analysing these outcome data without <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> resulted in an RR of 17.00 (95% CI 2.48 to 116.59; 2 RCTs, 21 participants; <a href="#CD004429-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD004429-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="IVIg versus placebo. Proportion of participants with an improvement in muscle strength. " data-id="CD004429-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>IVIg versus placebo. Proportion of participants with an improvement in muscle strength. </p> </div> </div> </div> </section> <section id="CD004429-sec-0074"> <p><b>Mean change in muscle strength expressed as standardised mean difference (SMD), assessed between two and six weeks after the last treatment and compared to baseline</b></p> <p>Mean muscle strength scores were available in three trials assessing 29 participants (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>). All three trials used only IVIg as the study treatment. </p> <p>Azulay and colleagues obtained a muscle score by summing the strength expressed in Newtons (N) assessed in two selected muscles that had to be impaired and were selected at the beginning of the study (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>). On average, muscle strength improved by 280 N on IVIg and decreased by 31 N on placebo. Federico and colleagues assessed grip strength with a handheld dynamometer (<a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>). Grip strength improved by 6.4 kg with IVIg treatment and worsened by 1.0 kg with placebo. The <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a> trial measured the Medical Research Council (MRC) sum score of 28 muscles (maximum score 140). The mean improvement after IVIg treatment was 3 points, whereas participants treated with placebo improved 1 point. The pooled SMD for all studies was 1.13 (95% CI −0.70 to 2.96; 3 RCTs, 29 participants). This indicated that the mean change in muscle strength on IVIg was approximately one standard deviation higher than the mean on placebo, but CI allowed for effects in either direction (<a href="#CD004429-fig-0005">Figure 5</a>; <a href="./references#CD004429-fig-0009" title="">Analysis 1.3</a>). </p> <div class="figure" id="CD004429-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="IVIg versus placebo. Change in mean muscle strength in participants without IVIg treatment at study entry." data-id="CD004429-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>IVIg versus placebo. Change in mean muscle strength in participants without IVIg treatment at study entry. </p> </div> </div> </div> </section> <section id="CD004429-sec-0075"> <p><b>Proportion of participants with a sustained improvement in disability at 12 months or later as determined and defined by the study authors</b></p> <p>None of the trials assessed or reported this outcome.</p> </section> <section id="CD004429-sec-0076"> <p><b>Proportion of participants in whom at least one conduction block resolved after therapy, assessed between two and six weeks after the last treatment and compared to baseline</b></p> <p>All four trials in immunoglobulin‐naive participants (n = 28) assessed and reported this outcome (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>; <a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>; <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>; <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). All of these trials used only IVIg as the study treatment. </p> <p>Resolution of at least one conduction block occurred six times after IVIg and never after placebo (RR 7.00, 95% CI 0.95 to 51.70; 4 RCTs, 28 participants; low‐certainty evidence). Analysing these outcome data without <a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a> resulted in an RR of 11.00 (95% CI 0.69 to 175.86; 3 RCTs, 22 participants; <a href="#CD004429-fig-0006">Figure 6</a>; <a href="./references#CD004429-fig-0010" title="">Analysis 1.4</a>). </p> <div class="figure" id="CD004429-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="IVIg versus placebo. Proportion of participants in whom at least 1 conduction block resolved after therapy. " data-id="CD004429-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>IVIg versus placebo. Proportion of participants in whom at least 1 conduction block resolved after therapy.  </p> </div> </div> </div> </section> </section> <section id="CD004429-sec-0077"> <h6 class="title">Maintenance treatment</h6> <p>For the secondary outcomes for studies with participants using immunoglobulin maintenance treatment, there was only one eligible study, involving 44 randomised participants, in which IVIg was used as the only study treatment (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). </p> <section id="CD004429-sec-0078"> <p><b>Proportion of immunoglobulin‐treated participants with an increase in disability during controlled IVIg/SCIg withdrawal as determined and defined by study authors</b></p> <p>Disability was measured using the upper limb portion of the Guy’s Neurological Disability Score. An increase in disability was reported in 17 of 42 evaluable participants (40%) after placebo and seven of 42 participants (17%) after IVIg. A higher proportion of participants deteriorated after switching from IVIg to placebo therapy as compared to those continuing on IVIg, with an RR of 2.43 (95% CI 1.13 to 5.24; 1 RCT, 42 participants; moderate‐certainty evidence; <a href="./references#CD004429-fig-0011" title="">Analysis 1.5</a>). </p> </section> <section id="CD004429-sec-0079"> <p><b>Proportion of immunoglobulin‐treated participants with a decrease in muscle strength during controlled IVIg/SCIg withdrawal as determined and defined by study authors</b></p> <p>In 42 evaluable participants, muscle strength was measured using the maximal grip strength of the more affected hand (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). The study used a cut‐off of 30% decrease of grip strength in the more affected hand to define a decline, which was a secondary outcome in the trial. Compared to baseline there was a decrease of grip strength in the most affected hand of 30% or more in four of 42 participants (10%) treated with IVIg compared to 20 of 42 participants (48%) treated with placebo. The proportion of participants with a decrease in muscle strength was lower in those receiving IVIg compared to those receiving placebo (RR 0.20, 95% CI 0.07 to 0.54; 1 RCT, 42 participants; moderate‐certainty evidence; <a href="./references#CD004429-fig-0012" title="">Analysis 1.6</a>). </p> </section> <section id="CD004429-sec-0080"> <p><b>Mean change in muscle strength expressed as SMD, assessed between two and six weeks after the last treatment and compared to baseline in participants on maintenance IVIg/SCIg treatment at study entry</b></p> <p>Maximal grip strength of the more affected hand increased by 3.75% after IVIg treatment and decreased by 31.38% after placebo treatment. There was an increase in muscle strength, with an SMD of 3.78 in favour of IVIg (95% CI 3.06 to 4.51; 1 RCT, 42 participants; <a href="./references#CD004429-fig-0013" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD004429-sec-0081"> <h6 class="title">Induction or maintenance treatment</h6> <section id="CD004429-sec-0082"> <p><b>Frequency of adverse effects attributable to treatment during the whole study period</b></p> <p>In one trial side effects were not mentioned (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>). During the double‐blind periods of the largest study, the rate of adverse events that were possibly caused by study treatment was 10% for IVIg (total of 242 infusions) and 12% for placebo (total of 129 infusions) (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). The report gave the number of participants with serious adverse events, but not adverse events; these data could not be included in the meta‐analysis. Two of 43 participants (4.7%) in this study reported one or more moderate or severe adverse effects after IVIg infusion, compared to 10 of 43 participants (23%) after placebo, regardless of causality. One serious adverse effect (pulmonary embolism) and 100 non‐serious adverse effects were encountered throughout four 12‐week IVIg treatment periods (three open‐label and one double‐blind). The other three studies reported only minor clinical side effects. Cutaneous rash and transient fever were seen in two participants out of five treated with IVIg in <a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>. Federico and colleagues noted minor side effects in 13 of 16 participants treated with IVIg: headache (5), headache and rash (3), rash alone (2), headache and malaise (1), anorexia, chills and fever (1), transient hypertension (1); and in one participant after placebo treatment: headache, fever and chills (<a href="./references#CD004429-bbs2-0002" title="FedericoP , ZochodneDW , FeasbyTE . Intravenous immunoglobulin treatment in multifocal motor neuropathy with conduction block: a double-blind, placebo-controlled, cross-over study. Neurology1999;52(Suppl 2):A127. FedericoP , ZochodneDW , HahnAF , BrownWF , FeasbyTE . Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology2000;55(9):1256-62. [PMID: 11087764]">Federico 2000</a>). Minor side effects were reported in <a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>, but were not attributable to individual participants and could not be included in the analysis. Participants in this study treated with IVIg complained of headache three times, flushing once, shivering twice, fever once, blurred vision twice and eczema once; the only reported side effect after placebo treatment was cold feet, in one participant. In the two meta‐analysed studies, adverse events occurred in 71% of people receiving IVIg and 4.8% of people receiving placebo, with a pooled RR for the development of side effects of 10.33 (95% CI 2.15 to 49.77; 2 RCTs, 21 participants; very low‐certainty evidence) (<a href="./references#CD004429-fig-0014" title="">Analysis 1.8</a>). </p> </section> </section> </section> </section> <section id="CD004429-sec-0083"> <h4 class="title">IVIg versus SCIg</h4> <p>One study compared the continuation of IVIg with a switch to SCIg in nine participants on IVIg maintenance treatment (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). Dynanometric muscle strength was the primary outcome measure; this study did not assess disability. See <a href="./full#CD004429-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD004429-sec-0084"> <h5 class="title">Primary outcome</h5> <section id="CD004429-sec-0085"> <h6 class="title">Proportion of participants with an improvement in disability between two and six weeks after the last treatment as determined and defined by the study authors and compared to baseline </h6> <p>The primary outcome could not be assessed for this study, as all participants were treated with IVIg at study entry. </p> </section> </section> <section id="CD004429-sec-0086"> <h5 class="title">Secondary outcomes</h5> <section id="CD004429-sec-0087"> <h6 class="title">Induction treatment</h6> <p>As all participants were known IVIg responders and received maintenance IVIg treatment, it was not possible to assess the secondary outcomes for induction treatment. </p> </section> <section id="CD004429-sec-0088"> <h6 class="title">Maintenance treatment </h6> <p>The only secondary outcomes for maintenance treatment available for analysis were mean change in muscle strength and the frequency of adverse effects attributable to treatment during the whole study period.  </p> <section id="CD004429-sec-0089"> <p><b>Mean change in muscle strength expressed as SMD, assessed between two and six weeks after the last treatment and compared to baseline in participants on maintenance IVIg/SCIg treatment at study entry</b></p> <p>Muscle strength was expressed as a combined dynamometric strength score assessed halfway between the two previous regular doses of IVIg for each participant. The strength of five to six affected muscle groups at three joints and at handgrip were taken and expressed as a percentage of normal strength. Selected muscles had to be impaired and were selected at the beginning of the study. The combined dynamometric strength score at baseline was similar in the two treatment arms: 69.5 ± 14% of normal strength in SCIg‐treated participants and 69.9 ± 18% of normal strength in IVIg‐treated participants. There was an increase of 3.6% (95% CI −3.6% to 10.9%) during SCIg treatment and an increase of 4.3% (95% CI −1.3% to 10.0%) during IVIg treatment. The evidence on muscle strength after SCIg compared to IVIg maintenance treatment was too uncertain for any conclusions to be drawn (SMD 0.08, 95% CI −0.84 to 1.00; 1 RCT, 9 participants; very low‐certainty evidence; <a href="./references#CD004429-fig-0015" title="">Analysis 2.1</a>). </p> </section> <section id="CD004429-sec-0090"> <p><b>Frequency of adverse effects attributable to treatment during the whole study period</b></p> <p>During SCIg treatment (84 days, range 36 to 112), six of nine participants reported adverse effects, all of which were reported to be mild and transient. One participant had sustained erythema and oedema at the injection sites, which required dose adjustments. Three of nine IVIg‐treated participants had a skin rash, phlebitis, or an infected implantable port. Evidence about adverse effects was too uncertain for any conclusions to be drawn (RR 0.50, 95% CI 0.18 to 1.40; 1 RCT, 9 participants; very low‐certainty evidence; <a href="./references#CD004429-fig-0016" title="">Analysis 2.2</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004429-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004429-sec-0091"></div> <section id="CD004429-sec-0092"> <h3 class="title" id="CD004429-sec-0092">Summary of main results</h3> <p>The review included six RCTs involving a total of 90 randomised participants with MMN. </p> <section id="CD004429-sec-0093"> <h4 class="title">Induction treatment with immunoglobulins </h4> <p>In immunoglobulin‐naive participants, low‐certainty evidence indicates that more people may experience an improvement in disability with initiation of IVIg treatment than with placebo; however, this finding is based on a small number of participants, and the estimated CIs are wide and also include the possibility of no effect. There is no evidence to support the use of SCIg as induction treatment in MMN.  </p> <p>Muscle strength improved spontaneously in one out of 27 participants (4%), but treatment with IVIg increased this chance of improvement to 78% (21 out of 27 participants). This absolute risk difference of 74% gives a number needed to treat for an additional beneficial outcome of 1.4. The percentage of participants with an improvement in disability was 39% with IVIg treatment and 11% with placebo. This difference in effect when outcome was measured at the disability level or at the impairment level is not surprising, since only 34 participants were studied. The power of the included studies together to detect a significant proportional difference at disability level between treated and untreated participants is low. For this reason, we graded the certainty of evidence for both disability and muscle strength as low. </p> <p>The mean muscle strength showed no important change after IVIg treatment compared to placebo, but the result was imprecise and allowed for effects in either direction. </p> <p>None of the trials reported or assessed the number of participants with a sustained improvement in disability (at 12 months). Low‐certainty evidence suggests that a higher proportion of participants had at least one conduction block resolved after IVIg treatment compared with placebo; the CIs also allowed for the possibility of no effect. </p> </section> <section id="CD004429-sec-0094"> <h4 class="title">Maintenance treatment with immunoglobulins</h4> <p>The need for ongoing treatment in most people with MMN was illustrated by Hahn and colleagues, as 40% of placebo participants deteriorated in disability, and 48% deteriorated in muscle strength (grip strength) by 30% or more in the more affected hand, based on moderate‐certainty evidence (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). When decline in participants' ability to perform activities of daily living was also considered, the proportion of untreated participants on placebo who deteriorated was 86%. This emphasises that the disability scale used (Guy's Neurological Disability Score) and grip strength do not capture all changes that can interfere with daily living. Nevertheless, it is also important to note that 14% of participants on placebo did not experience deterioration, although the 12‐week placebo period might have been too short for this to be experienced by some participants. </p> <p>SCIg might be an alternative to IVIg maintenance treatment. A single trial assessed the feasibility of switching participants from IVIg to SCIg. The trial did not address disability. Muscle strength remained stable in participants switching from IVIg maintenance treatment to SCIg, but due to the very low certainty of the evidence we cannot draw any conclusions (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). </p> </section> <section id="CD004429-sec-0095"> <h4 class="title">Adverse events</h4> <p>The evidence for all adverse events estimates was of very low certainty. Based on reported data of 21 participants treated with IVIg that could be meta‐analysed, 71% of participants experienced any adverse events during the trial, compared to 4.8% receiving placebo. One participant treated with IVIg had a pulmonary embolism, which was regarded as a serious adverse event. </p> <p>In the trial comparing IVIg with SCIg, mild transient side effects were reported in 33% of participants treated with IVIg and 66% of those treated with SCIg. SCig side effects were all related to injection‐site reactions, with erythema, itch, and tenderness. </p> </section> <section id="CD004429-sec-0096"> <h4 class="title">Cost</h4> <p>Cost‐utility analyses of immunoglobulins used in MMN have not been published. A cost‐utility study has been done in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), which showed that compared with prednisolone, IVIg is likely to be cost‐effective in this group (<a href="./references#CD004429-bbs2-0075" title="McCroneP , ChisholmD , KnappM , HughesR , ComiG , DalakasMC , et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculopathy. European Journal of Neurology2003;10(6):687-94.">McCrone 2003</a>). However, the analyses also showed that this cost‐effectiveness was greatly dependent on the price and the amount of IVIg administered. Furthermore, corticosteroids are not used in MMN. Given these factors, it is uncertain whether the outcome of this study can be extrapolated to the MMN population. </p> </section> </section> <section id="CD004429-sec-0097"> <h3 class="title" id="CD004429-sec-0097">Overall completeness and applicability of evidence</h3> <p>Not all outcomes on efficacy were addressed in this review. One trial documented patient global assessment of change, for which there was no change between assessments in those receiving IVIg compared to reports of minimal worsening to much worse in those receiving placebo (<a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>). When comparing IVIg to SCIg treatment (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>), four out of nine cases preferred SCIg due to lack of end‐of‐dose deterioration and the ability to receive treatment at home, compared to two participants who preferred IVIg due to the avoidance of several treatments required in one week. The use of hyaluronidase in combination with SCIg has been reported to enable a reduction of SCIg dosing frequency, which may improve patient preference (<a href="./references#CD004429-bbs2-0015" title="HerraetsIJT , BakersJNE , vanEijkRPA , GoedeeHS , van derPolWL , vanden BergLH . Human immune globulin 10% with recombinant human hyaluronidase in multifocal motor neuropathy. Journal of Neurology2019;266(11):2734-42. [PMID: 31325017]">Herraets 2019</a>), but more trial data are required to define which therapy is considered superior. </p> <p>No long‐term outcomes were reported, and data from small RCTs do not allow adequate assessment of adverse events. </p> <section id="CD004429-sec-0098"> <h4 class="title">Certainty of the evidence</h4> <section id="CD004429-sec-0099"> <h5 class="title">Induction treatment with immunoglobulins</h5> <p>We downgraded the certainty of the evidence for all outcomes to low because of imprecision due to study limitations, small sample sizes, and wide CI. The CI for disability between two and six weeks after the last treatment encompassed both a clinically relevant effect in favour of IVIg and little or no effect. The power of the included studies to detect a significant proportional difference at disability level between treated and untreated participants was low. </p> <p>In clinical phase III trials, the primary outcome should be disability and not impairment, as the primary question to be answered is whether a person benefits from a particular treatment. From this point of view, our evidence is less certain that people with MMN will benefit from IVIg treatment. However, since weakness is the only determinant of disability in people with MMN, it is to be expected that in those whose muscle strength improves after IVIg treatment, disability will improve as well. </p> <p>Another reason for the divergent results between disability and muscle strength could be the fact that the disability scales used in the three trials are not reliable and tailored for use in people with MMN and are unresponsive to change. Three different disability scales were used: the modified Norris scale (<a href="./references#CD004429-bbs2-0001" title="AzulayJP , BlinO , PougetJ , BoucrautJ , Billé-TurcF , CarlesG , et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology1994;44(3 Pt 1):429-32. [PMID: 8145910]">Azulay 1994</a>), the modified Rankin scale (<a href="./references#CD004429-bbs2-0006" title="Van den BergLH , KerkhoffH , OeyPL , FranssenH , MolleeI , VermeulenM . Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. Journal of Neurology, Neurosurgery and Psychiatry1995;59(3):248-52. [PMID: 7673950]">Van den Berg 1995</a>), and a self‐evaluation scale scored from zero (normal) to five (impossible) for five motor activities of daily life, chosen for each participant together with the examiner at baseline (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>). The Norris scale, which evaluates limb function, was designed for amyotrophic lateral sclerosis (ALS) assessment and is a combined disability and impairment scale (<a href="./references#CD004429-bbs2-0086" title="Norris FH Jr, CalanchiniPR , FallatRJ , PancharisS , JewettB . Administration of guanidine in amyotrophic lateral sclerosis. Neurology1974;24(8):721-8.">Norris 1974</a>). The combination of disability and impairment in one scale potentially confuses the clinical interpretation of changes on such a scale and should be avoided. Furthermore, this scale has not been evaluated for use in people with MMN. The modified Rankin score measures disability, and has been shown to be reliable and valid in assessing people with neuropathy (<a href="./references#CD004429-bbs2-0043" title="deHaanR , AaronsonN , LimburgM , HewerRL , vanCrevelH . Measuring quality of life in stroke. Stroke1993;24(2):320-7.">de Haan 1993</a>; <a href="./references#CD004429-bbs2-0078" title="MolenaarDSM . Chronic Inflammatory Demyelinating Polyneuropathy: Diagnosis, Treatment, and Outcome Assessment [Thesis]. University of Amsterdam, 1998. [ISBN 90-9012174-9]">Molenaar 1998</a>; <a href="./references#CD004429-bbs2-0079" title="MolenaarDSM , VermeulenM , deVisserM , deHaanR . Impact of neurological signs and symptoms on functional status in patients with peripheral neuropathies. Neurology1999;52(1):151-6.">Molenaar 1999</a>); however, whether this is also true for people with MMN with predominantly upper limb and focal involvement has not been investigated. The disability scale used by Léger and colleagues seems to be more tailored for use in people with MMN. However, this scale has not been formally evaluated for reliability, validity, responsiveness, and inter‐ and intrarater variability in people with MMN (<a href="./references#CD004429-bbs2-0005" title="LégerJM , ChassandeB , MussetL , MeiningerV , BoucheP , BaumannN . Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain2001;124(1):145-53. [PMID: 11133794]">Léger 2001</a>). </p> <p>The results from the other outcomes (i.e. mean change in muscle strength, proportion of participants with an improvement in disability at 12 months or later, and proportion of participants in which at least one conduction block has resolved after therapy) all supported the efficacy of IVIg in MMN for induction treatment, but had the same limitations, that is small numbers of participants or events and wide CIs.  </p> <p>As previously stated, there is no evidence to support the use of SCIg as induction treatment in MMN.  </p> </section> <section id="CD004429-sec-0100"> <h5 class="title">Maintenance treatment with immunoglobulins</h5> <p>The <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a> trial, which examined the need for ongoing IVIg treatment in people with MMN, was the largest study in the review, with 44 randomised participants. The data, whilst imprecise, showed clear effects on disability and strength, and we considered the certainty of evidence for these effects to be moderate. We considered the 12‐week wash‐out period to be short, but did not consider this to be a serious study limitation. </p> <p>Muscle strength remained stable in participants switching from IVIg maintenance treatment to SCIg in the one RCT evaluating SCIg in MMN (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). The major limitation of this study was the short study period, in which an IVIg carry‐over effect could have occurred. <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a> included only nine participants, and we downgraded the certainty of the evidence twice for very serious imprecision. </p> </section> <section id="CD004429-sec-0101"> <h5 class="title">Adverse events</h5> <p>Although adverse events were reported in the included studies, the estimate of the occurrence and severity of adverse events with IVIg and SCIg is better made based on large observational studies with long‐term follow up rather than small trials, including studies on more prevalent diseases such as CIDP. Non‐RCT evidence on adverse events is presented in the <a href="#CD004429-sec-0103">Agreements and disagreements with other studies or reviews</a> section of the review. </p> <p>The certainty of the evidence is mostly limited due to the small sample size of the included trials. However, the trials provided mostly homogenous results, in which all relevant outcomes suggested efficacy of IVIg in MMN, albeit with low certainty. </p> </section> </section> </section> <section id="CD004429-sec-0102"> <h3 class="title" id="CD004429-sec-0102">Potential biases in the review process</h3> <p>Due to the rarity of MMN, the number of participants included in each trial was low. All of the included trials used a cross‐over design. Such a trial design is suitable for evaluating interventions with a temporary effect in the treatment of stable, chronic conditions, for which MMN would be applicable. Carry‐over of treatment effect is a potential bias of such studies; this was mitigated against in each trial through the inclusion of wash‐out periods. Reporting of the cross‐over trials was variable, as some studies did not provide individual data or sufficient details on used statistical methods to confirm that appropriate paired analysis was performed, especially for the proportional outcomes. For this reason we were not able to perform a paired analysis for meta‐analysis, thus we analysed results from treatment versus placebo groups as if the trial were a parallel‐group trial comparing the two. This approach gives rise to a unit of analysis error, which resulted in relatively broad CIs. However, the analysis is conservative, and thus the statistically significant findings discussed in the results are under‐weighted. </p> </section> <section id="CD004429-sec-0103"> <h3 class="title" id="CD004429-sec-0103">Agreements and disagreements with other studies or reviews</h3> <section id="CD004429-sec-0104"> <h4 class="title">Induction treatment with immunoglobulins</h4> <p>There are many open and uncontrolled studies of IVIg initiation in MMN. The reported response to IVIg in larger retrospective studies varies between 67% and 94% (<a href="./references#CD004429-bbs2-0032" title="AzulayJP , RihetP , PougetJ , CadorF , BlinO , BoucrautJ , et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. Journal of Neurology, Neurosurgery and Psychiatry1997;62(4):391-4.">Azulay 1997</a>; <a href="./references#CD004429-bbs2-0034" title="BoucheP , MoulonguetA , Younes-ChennoufiAB , AdamsD , BaumannN , MeiningerV , et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. Journal of Neurology, Neurosurgery and Psychiatry1995;59(1):38-44.">Bouche 1995</a>; <a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>; <a href="./references#CD004429-bbs2-0023" title="LégerJM , VialaK , CancalonF , MaisonobeT , GruwezB , WaegemansT , et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. Journal of Neurology, Neurosurgery and Psychiatry2008;79(1):93-6. ">Léger 2008</a>; <a href="./references#CD004429-bbs2-0083" title="Nobile-OrazioE , CappellariA , MeucciN , CarpoM , TerenghiF , BersanoA , et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. Journal of Neurology, Neurosurgery and Psychiatry2002;72(6):761-6.">Nobile‐Orazio 2002</a>; <a href="./references#CD004429-bbs2-0104" title="TerenghiF , CappellariA , BersanoA , CarpoM , BarbieriS , Nobile-OrazioE . How long is IVIg effective in multifocal motor neuropathy?Neurology2004;62(4):666-8.">Terenghi 2004</a>), which is comparable with the rate of muscle strength improvement found in this review. </p> </section> <section id="CD004429-sec-0105"> <h4 class="title">Maintenance treatment with immunoglobulins </h4> <p>The need for ongoing treatment in most participants with MMN was illustrated by <a href="./references#CD004429-bbs2-0003" title="EUCTR2009-013841-27-DK. A randomized, double-blind, placebo controlled, cross-over study of the effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of multifocal motor neuropathy - IGIV, 10% MMN Trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-013841-27-DK (first received 27 October 2009). HahnAF , Beydoun SR, LawsonV , OhM , EmpsonVG , GelmontD , et al. A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IVIG) for the treatment of multifocal motor neuropathy (MMN). Journal of the Peripheral Nervous System2012;17(2):243-4. HahnAF , BeydounSR , LawsonV , for The IVIG in MMN Study Team, OhM , EmpsonVG , LeiblH , et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. Journal of the Peripheral Nervous System2013;18(4):321-30. [EMBASE: 370497088]KoskiCL , BeydounSR , LawsonV , OhM , GelmontD , EmpsonVG . A phase III, randomized, placebo-controlled study of the efficacy and safety of 10% liquid intravenous immunoglobulin (IGIV) for the treatment of multifocal motor neuropathy (MMN). PM &amp; R: Journal of Injury, Function, and Rehabilitation2013;5(9S):S152. NCT00666263. Study of the effectiveness of intravenous immune globulin (10%) for the treatment of multifocal motor neuropathy. clinicaltrials.gov/ct2/show/study/NCT00666263 (first received 24 April 2008). ">Hahn 2013</a>. This is in line with the largest retrospective study, including 88 people with MMN, in which four IVIg responders (5%) did not require ongoing treatment (<a href="./references#CD004429-bbs2-0012" title="CatsEA , van derPolWL , PiepersS , FranssenH , JacobsBC , vanden Berg-VosRM , et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology2010;75(9):818-25. ">Cats 2010</a>). In another study involving 40 participants, IVIg withdrawal was possible in 22% of participants (<a href="./references#CD004429-bbs2-0023" title="LégerJM , VialaK , CancalonF , MaisonobeT , GruwezB , WaegemansT , et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. Journal of Neurology, Neurosurgery and Psychiatry2008;79(1):93-6. ">Léger 2008</a>). Nevertheless, it is also important to note that 14% of participants did not experience deterioration, although the 12‐week placebo period might have been too short for some participants to experience deterioration. In other chronic inflammatory neuropathies, such as CIDP, periodic immunoglobulin withdrawals are recommended to determine immunoglobulin dependency. Whether and when IVIg withdrawals should be attempted in people with MMN is unknown. </p> <p>Muscle strength remained stable in participants switching from IVIg maintenance treatment to SCIg in the included RCT of SCIg maintenance treatment in MMN (<a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). In an open‐label, prospective study, four of five participants remained stable after switching to SCIg when SCIg was administered in equal monthly doses to the individual pre‐study IVIg dose (<a href="./references#CD004429-bbs2-0014" title="EftimovF , VermeulenM , De HaanRJ , Van den BergLH , Van SchaikIN . Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. Journal of the Peripheral Nervous System2009;14(2):93-100. ">Eftimov 2009</a>). Participants who received lower SCIg dosages compared to pre‐study IVIg dose deteriorated, suggesting that at least equal SCIg doses are needed to maintain clinical efficacy of immunoglobulin therapy. In a 2014 prospective observational study, 21 of 22 people (95%) with MMN and wearing‐off signs during maintenance IVIg treatment were switched to SCIg and remained stable in disability (<a href="./references#CD004429-bbs2-0038" title="CocitoD , MerolaA , PeciE , MazzeoA , FazioR , FranciaA , et al. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. Journal of Neurology2014;261(11):2159-64.">Cocito 2014</a>). </p> </section> <section id="CD004429-sec-0106"> <h4 class="title">Adverse events</h4> <p>Only one serious side effect was reported in this review, but mild, transient side effects were reported in 71% of those treated with IVIg, which is more than has been reported in the literature on non‐randomised studies (<a href="./references#CD004429-bbs2-0046" title="DuhemC , DicatoMA , RiesF . Side-effects of intravenous immune globulins. Clinical &amp; Experimental Immunology1994;97(Suppl 1):79-83.">Duhem 1994</a>; <a href="./references#CD004429-bbs2-0073" title="MartinTD . Safety and tolerability of intravenous immunoglobulins. In: SaidG , editors(s). Treatment of Neurological Disorders With Intravenous Immunoglobulins. London: Martin Duntiz, 2000:181-91.">Martin 2000</a>; <a href="./references#CD004429-bbs2-0103" title="StiehmER . Immunoglobulin therapy in primary antibody deficiency and HIV infection. In: KazatchkineMD , MorellA , editors(s). Intravenous Immunoglobulin: Research and Therapy. 1st edition. Pearl River, NY: Parthenon Publishing, 1996:193-203.">Stiehm 1996</a>). </p> <p>Most side effects of IVIg are mild and transient, and are estimated to occur in 1% to 15% of infusions (<a href="./references#CD004429-bbs2-0041" title="DalakasMC , ClarkWM . Strokes, thromboembolic events, and IVIg. Rare incidents blemish an excellent safety record. Neurology2003;60(11):1736-7.">Dalakas 2003</a>; <a href="./references#CD004429-bbs2-0046" title="DuhemC , DicatoMA , RiesF . Side-effects of intravenous immune globulins. Clinical &amp; Experimental Immunology1994;97(Suppl 1):79-83.">Duhem 1994</a>; <a href="./references#CD004429-bbs2-0047" title="EijkhoutHW , vanAkenWG . Blood components, plasma and plasma products. In: AronsenJK , editors(s). Side Effects of Drugs Annual. 14th edition. Amsterdam: Elsevier, 2002:398-404.">Eijkhout 2002</a>; <a href="./references#CD004429-bbs2-0103" title="StiehmER . Immunoglobulin therapy in primary antibody deficiency and HIV infection. In: KazatchkineMD , MorellA , editors(s). Intravenous Immunoglobulin: Research and Therapy. 1st edition. Pearl River, NY: Parthenon Publishing, 1996:193-203.">Stiehm 1996</a>; <a href="./references#CD004429-bbs2-0118" title="WittstockM , BeneckeR , ZettlUK . Therapy with intravenous immunoglobulins: complications and side-effects. European Neurology2003;50(3):172-5.">Wittstock 2003</a>). Rashes, chills, fever, mild hypo‐ or hypertension, nausea, malaise, headache, and mild arthralgias seem to occur most frequently. Occasionally, a short‐lasting aseptic meningitis may occur without or with only minimal long‐term sequelae. The most worrisome, albeit rare, complications are severe and potentially fatal anaphylactic shock, thromboembolic events, and temporary renal impairment, which is relatively common in individuals with pre‐existing renal disease (<a href="./references#CD004429-bbs2-0041" title="DalakasMC , ClarkWM . Strokes, thromboembolic events, and IVIg. Rare incidents blemish an excellent safety record. Neurology2003;60(11):1736-7.">Dalakas 2003</a>; <a href="./references#CD004429-bbs2-0095" title="PierceLR , JainN . Risks associated with the use of intravenous immunoglobulin. Transfusion Medicine Reviews2003;17(4):241-51.">Pierce 2003</a>). The exact incidence of these severe side effects is unknown (<a href="./references#CD004429-bbs2-0041" title="DalakasMC , ClarkWM . Strokes, thromboembolic events, and IVIg. Rare incidents blemish an excellent safety record. Neurology2003;60(11):1736-7.">Dalakas 2003</a>), although one study estimated the risk of thromboembolic events at 1% of infusions (<a href="./references#CD004429-bbs2-0097" title="RajaballyYA , KearneyDA . Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. Journal of the Neurological Sciences2011;308(1878-5883 (Electronic), 0022-510X (Linking), 1-2):124-7.">Rajabally 2011</a>). A more recent study demonstrated a thromboembolic event odds ratio of 53.6 in people on IVIg, compared to 7.6 in the general population (<a href="./references#CD004429-bbs2-0063" title="KapoorM , SpillaneJ , EnglezouC , Sarri-GonzalezS , BellR , RossorA . Thromboembolic risk with IVIg. Incidence and risk factors in patients with inflammatory neuropathy. Neurology2020;94(6):e635-8.">Kapoor 2020</a>). In an ongoing postmarketing clinical pharmacovigilance study, an adverse reaction rate of less than 0.5% for more than 26,000 infusions and less than 4% in 2554 people has been reported (<a href="./references#CD004429-bbs2-0073" title="MartinTD . Safety and tolerability of intravenous immunoglobulins. In: SaidG , editors(s). Treatment of Neurological Disorders With Intravenous Immunoglobulins. London: Martin Duntiz, 2000:181-91.">Martin 2000</a>). </p> <p>Alternatively, SCIg more often leads to local adverse reaction, with a reported frequency of adverse events of 17% in a large study of people with primary immunodeficiencies (<a href="./references#CD004429-bbs2-0051" title="GardulfA , AndersenV , BjörkanderJ , EricsonD , FrolandSS , GustafsonR , et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet1995;345(8946):365–9.">Gardulf 1995</a>). These local adverse reactions are usually minor, generally considered acceptable, and present especially when initiating treatment (<a href="./references#CD004429-bbs2-0038" title="CocitoD , MerolaA , PeciE , MazzeoA , FazioR , FranciaA , et al. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. Journal of Neurology2014;261(11):2159-64.">Cocito 2014</a>; <a href="./references#CD004429-bbs2-0014" title="EftimovF , VermeulenM , De HaanRJ , Van den BergLH , Van SchaikIN . Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. Journal of the Peripheral Nervous System2009;14(2):93-100. ">Eftimov 2009</a>; <a href="./references#CD004429-bbs2-0004" title="HarboT , AndersenH , HessA , HansenK , SindrupSH , JakobsenJ . Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. European Journal of Neurology2009;16(5):631-8. [PMID: 19236457]HarboT , AndersenH , SindrupS , HansenK , JakobsenJ . Subcutaneous versus intravenous immunoglobulin treatment for MMN patients: a randomized, single-blinded, cross-over study. European Journal of Neurology2008;15(Suppl 3):15-6. NCT00268788. Subcutaneous immunoglobulin treatment for multifocal motor neuropathy. www.clinicaltrials.gov/ct2/show/NCT00268788 (first received 22 December 2005). ">Harbo 2009</a>). However, systemic adverse events are less frequent compared to IVIg. Based on these recent small studies, there is limited evidence that SCIg can be used as a substitute for maintenance IVIg treatment. People with poor venous access and recurring systemic adverse reaction after IVIg might be particularly good candidates for this alternative, but more evidence is needed to confirm the efficacy of SCIg. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004429-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study selection flow chart." data-id="CD004429-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study selection flow chart.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: red (‐) = high risk of bias, yellow (?) = unclear risk of bias, green (+) = low risk of bias." data-id="CD004429-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. Key: red (‐) = high risk of bias, yellow (?) = unclear risk of bias, green (+) = low risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-FIG-03" target="_blank"><b></b></a></p> </div><img alt="IVIg versus placebo. Proportion of participants with an improvement in disability as determined and defined by the study authors. In all forest plots, the 'Total' columns show the number of observations." data-id="CD004429-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>IVIg versus placebo. Proportion of participants with an improvement in disability as determined and defined by the study authors. In all forest plots, the 'Total' columns show the number of observations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-FIG-04" target="_blank"><b></b></a></p> </div><img alt="IVIg versus placebo. Proportion of participants with an improvement in muscle strength. " data-id="CD004429-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>IVIg versus placebo. Proportion of participants with an improvement in muscle strength. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-FIG-05" target="_blank"><b></b></a></p> </div><img alt="IVIg versus placebo. Change in mean muscle strength in participants without IVIg treatment at study entry." data-id="CD004429-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>IVIg versus placebo. Change in mean muscle strength in participants without IVIg treatment at study entry. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-FIG-06" target="_blank"><b></b></a></p> </div><img alt="IVIg versus placebo. Proportion of participants in whom at least 1 conduction block resolved after therapy. " data-id="CD004429-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>IVIg versus placebo. Proportion of participants in whom at least 1 conduction block resolved after therapy.  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 1: Proportion of participants with an improvement in disability as determined and defined by the study authors" data-id="CD004429-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 1: Proportion of participants with an improvement in disability as determined and defined by the study authors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 2: Proportion of participants with an improvement in muscle strength" data-id="CD004429-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 2: Proportion of participants with an improvement in muscle strength </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 3: Change in mean muscle strength in participants without IVIg treatment at study entry" data-id="CD004429-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 3: Change in mean muscle strength in participants without IVIg treatment at study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 4: Proportion of participants in whom at least 1 conduction block resolved after therapy" data-id="CD004429-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 4: Proportion of participants in whom at least 1 conduction block resolved after therapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 5: Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as defined and determined by the study authors" data-id="CD004429-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 5: Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as defined and determined by the study authors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 6: Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal, as defined and determined by the study authors" data-id="CD004429-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 6: Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal, as defined and determined by the study authors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 7: Change in mean muscle strength in participants with IVIg treatment at study entry" data-id="CD004429-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 7: Change in mean muscle strength in participants with IVIg treatment at study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: IVIg versus placebo, Outcome 8: Proportion of participants with side effects attributable to treatment" data-id="CD004429-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: IVIg versus placebo, Outcome 8: Proportion of participants with side effects attributable to treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IVIg versus SCIg maintenance, Outcome 1: Change in mean muscle strength in participants with IVIg treatment at study entry" data-id="CD004429-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: IVIg versus SCIg maintenance, Outcome 1: Change in mean muscle strength in participants with IVIg treatment at study entry </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004429-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/urn:x-wiley:14651858:media:CD004429:CD004429-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: IVIg versus SCIg maintenance, Outcome 2: Proportion of participants with side effects attributable to treatment" data-id="CD004429-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_t/tCD004429-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: IVIg versus SCIg maintenance, Outcome 2: Proportion of participants with side effects attributable to treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/media/CDSR/CD004429/image_n/nCD004429-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004429-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">IVIg compared to placebo for multifocal motor neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IVIg compared to placebo for multifocal motor neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with multifocal motor neuropathy<br/><b>Settings:</b> variable: home, centre, or study site<br/><b>Intervention:</b> intravenous immunoglobulin (IVIg)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVIg</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Induction</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with an improvement in disability scale used in the original study </p> <p>Follow‐up: 2 to 6 weeks after the last IVIg treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 100<br/>(10 to 112) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.00</b><br/>(0.89 to 10.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (36 observations)<br/>(3 cross‐over RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg treatment may improve disability, although the result is also consistent with no effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with an improvement of muscle strength</p> <p>Follow‐up: 2 to 6 weeks after the last IVIg treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 100<br/>(11 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11.00</b><br/>(2.86 to 42.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (54 observations)<br/>(3 cross‐over RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg treatment may improve muscle strength.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with an improvement in disability at 12 months or later</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants in which at least 1 conduction block resolved after therapy</p> <p>Follow‐up: 2 to 6 weeks after the last IVIg treatment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 100</p> <p>(event rate 0 in 28)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not calculable</p> <p>(event rate 6 in 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7.00</b> </p> <p>(0.95 to 51.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (56 observations)</p> <p>(4 cross‐over RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg treatment may increase the proportion of people with resolution of at least 1 conduction block; however, the data are also consistent with no effect. </p> <p>In general, spontaneous resolution of conduction block is considered rare, although axonal damage can lead to too low amplitudes to assess the presence of a conduction block. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Maintenance</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as determined and defined by study authors </p> <p>Follow‐up: day 8 of 2‐week treatment cycle, day 15 of those treated every 3 or 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 100<br/>(19 to 87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b><br/>(1.13 to 5.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (84 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg withdrawal probably leads to deterioration in disability.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal </p> <p>Follow‐up: day 8 of 2‐week treatment cycle, day 15 of those treated every 3 or 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100 (3 to 26)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.2</b> (0.07 to 0.54)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (84 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVIg withdrawal probably leads to deterioration in muscle strength.</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Adverse effects (induction or maintenance)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with side effects attributable to treatment</p> <p>Follow‐up: day 8 of 2‐week treatment cycle, day 15 of those treated every 3 or 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 100 (10 to 100)<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 10.33</b><br/>(2.15 to 49.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (42 observations)<br/>(2 cross‐over RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is too uncertain to determine whether adverse effects attributable to treatment are more or less common with IVIg than with placebo. </p> <p>1 trial report did not mention adverse effects. In 1 trial, minor adverse effects occurred but were not attributed to individual participants and therefore could not be included in the meta‐analysis. A third trial reported the number of infusions in which adverse events occurred and not the number of participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IVIg:</b> intravenous immunoglobulin; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b><br/>  </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for imprecision: small sample size.<br/><sup>b</sup>Downgraded once for study limitations: the studies provided insufficient detail for some risk of bias assessments, and two studies were at high risk of bias for blinding. Although the scales used to measure disability in the included studies were not tailored to multifocal motor neuropathy, this did not warrant further downgrading for indirectness.<br/><sup>c</sup>We downgraded a second time for imprecision, as only six events occurred. We did not further downgrade the evidence for study limitations, as diagnosis of a conduction block is unlikely to be affected by lack of blinding.<br/><sup>d</sup>We did not downgrade for study limitations. Although the trial was at unclear risk of other bias due to a short placebo period with possible incomplete IVIg wash‐out, this would tend to lead to an underestimation of withdrawal effects rather than an exaggeration.<br/><sup>e</sup>We downgraded the evidence a second time for imprecision, as the evidence involved two small trials and few events. We also downgraded the evidence because the studies provided insufficient detail for some risk of bias assessments, and one of the two trials was at high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">IVIg compared to placebo for multifocal motor neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004429-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">IVIg compared to SCIg for multifocal motor neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IVIg compared to SCIg for multifocal motor neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with multifocal motor neuropathy<br/><b>Settings:</b> initial short hospital stay of 1 to 3 days, followed by self‐administration at home supervised by telephone calls from the study nurse<br/><b>Intervention:</b> intravenous immunoglobulin (IVIg)<br/><b>Comparison:</b> subcutaneous immunoglobulin (SCIg) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SCIg</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>IVIg</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Induction</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No trial studied the use of SCIg for induction. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Maintenance</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in mean muscle strength in participants on IVIg treatment at study entry</p> <p>Follow‐up: 10 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in mean muscle strength in participants on IVIg treatment at study entry in the intervention group was <b>0.08 SD higher</b> (−0.84 lower to 1.00 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (18 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain for the effects on muscle strength of maintenance treatment with SCIg vs IVIg. </p> <p> </p> <p>As a rule of thumb, an effect size of 0.2 would be a small effect; 0.08 is unlikely to be important (<a href="./references#CD004429-bbs2-0039" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates Inc, 1988.">Cohen 1988</a>). </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with side effects attributable to treatment</p> <p>Follow‐up: baseline to final evaluation 105 days (45 to 140)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> (12 to 93)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.50 (0.18 to 1.40)<br/>  </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (18 observations)<br/>(1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is uncertain for adverse effects attributable to maintenance treatment with SCIg vs IVIg. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>IVIg</b> : intravenous immunoglobulin; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>SCIg:</b> subcutaneous immunoglobulin; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations: a single‐blinded RCT in which participants were not blinded for outcome. The study period per treatment arm varied between 54 and 168 days, which may have led to a considerable carry‐over effect in receiving SCIg, especially in participants with a shorter treatment period.<br/><sup>b</sup>Downgraded twice for imprecision: a single trial with a small sample size (9 people, 18 observations). The event rate for adverse events was very low (3 of 9 participants on IVIg versus 6 of 9 participants on placebo). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">IVIg compared to SCIg for multifocal motor neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/full#CD004429-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004429-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IVIg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Proportion of participants with an improvement in disability as determined and defined by the study authors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.89, 10.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Without study van den Berg 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.53, 7.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Study van den Berg 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.44, 111.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Proportion of participants with an improvement in muscle strength <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [2.86, 42.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Without study van den Berg 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.00 [2.48, 116.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Study van den Berg 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [0.81, 31.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in mean muscle strength in participants without IVIg treatment at study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [‐0.70, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Proportion of participants in whom at least 1 conduction block resolved after therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.95, 51.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Without study van den Berg 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.00 [0.69, 175.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Study van den Berg 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.15, 61.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal, as defined and determined by the study authors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.13, 5.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal, as defined and determined by the study authors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.07, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Change in mean muscle strength in participants with IVIg treatment at study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [3.06, 4.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Proportion of participants with side effects attributable to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.33 [2.15, 49.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">IVIg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004429-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IVIg versus SCIg maintenance</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in mean muscle strength in participants with IVIg treatment at study entry <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.84, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Proportion of participants with side effects attributable to treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.18, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IVIg versus SCIg maintenance</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004429.pub3/references#CD004429-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004429.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004429-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004429-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004429-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD004429-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD004429-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD004429-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD004429-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD004429-note-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD004429-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004429\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004429\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004429\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004429\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004429\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004429.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004429.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004429.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004429.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004429.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726066215"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004429.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726066218"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004429.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8a92980c9379',t:'MTc0MDcyNjA2Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 